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3ABSTRACT
Protective immunity to influenza virus correlates with levels of neutralising antibodies 
directed against haemagglutinin (HA), the major membrane glycoprotein of the virus. The 
antibodies exert selective pressure resulting in the recurrent and annual emergence of new 
variant viruses.
Although all five antigenic sites are implicated in antibody recognition, immunodominance is 
evident in the secondary antibody response, following natural Infection of inbred mice as has 
been shown in this laboratory; BALB/c (H-2d) mAbs predominantly recognise HA1 198, and 
CBA/Ca (H-2k) mAbs, HA1 158, as deduced by sequencing the HA genes of X31 laboratory 
variants. Such restriction in the antibody response raises several questions concerning the 
mechanisms involved in repertoire selection and the structural basis of the selection 
process, which this investigation attempted to address using transgenic mice expressing 
human Ig p chains.
The purpose of examining the memory repertoire for influenza HA in transgenic mice was to 
determine whether restricted Vh region gene usage and/or inability to class switch 
(lgM->lgG) with a resultant lack of affinity maturation would restrict the potential antibody 
repertoire. I have demonstrated, by structural analysis of variant virus HA genes, selected 
with mAbs expressing human p, chains, that there is a preferential selection for mutations 
within conserved residues that constitute part of the receptor binding site (HA1 225, HA1 
226) that do not occur in previously documented laboratory variants. Also the majority of 
these variant viruses have amino acid substitutions at twp different positions: (HA1 145,
226) or (HA1 135, 225) or (HA1 135, 158) or (HA1 145, 158).
4In the second part of this study, I have examined the influence of conœmitant immunity to 
X31 on re-challenge with an X31 variant virus in an attempt to mimic the human situation of 
recurrent infection: CBA/Ca mice were infected intranasally with X31 and their neutralising 
antibody repertoire investigated by hemisplenectomy, mAb production, X31 variant selection 
and sequencing of their HA genes. Following a rest period, mice were re-challenged with a 
laboratory variant, A43, differing from X31 at known antigenic sites (HA1 145,158, del 224- 
230) and which was not recognised by the majority of mAbs from the primary challenge.
The mAbs, established after re-infection with A43, showed heteroclitic reactivity forX31 and 
selected laboratory variants thereof, with substitutions at both conserved residues within the 
receptor binding site and at known antigenic sites (HA1 193,198, 226) or HA1 (198, 223).
I have demonstratedjn two different systems (a) human IgH transgenic mice, or (b) 
recurrent infection with a variant virus, that there is preferentiai seiectlon of laboratory 
mutants containing multiple substitutions, including changes in conserved residues that 
constitute part of the receptor-binding pocket (HA1 225 or 226). This has led me to 
conclude that antibody affinity might play a determinant role in the selection of mutations 
that affect receptor binding function. The majority of X31 variants that I have cloned, and 
characterised, do indeed have altered receptor-binding specificity as shown by their 
resistance to horse serum inhibition of haemagglutination and/or altered binding to 
neoglycpproteins containing terminal a  2,3 or a  2,6 sialyl residues.
Reduced affinity of the neutralising Ab response during infection - such as in the 
immunocompromised, or the very young or very old, or due to previous exposure to a 
related virus might skew the antibody repertoire to selection of receptor-binding variants and 
therefore be a further determinant of antigenic drift.
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CHAPTER-1
Introduction
2 0
1. GENERAL INTRODUCTION
1.1. Immune recognition
The binding of foreign antigens to complementary structures on the 
surface of B and T lymphocytes represents the initial step in the sequence of 
events leading to activation of both cellular and humoral arms of the immune 
system which recognise antigen rather differently. Membrane immunoglobulin 
(Ig), first as a receptor molecule on the surface of B lymphocytes and later as a 
soluble molecule, binds antigen in an unprocessed or native state. T cell 
receptors (TcR), on the other hand, bind antigen only in association with major 
histocompatibility complex (MHC) proteins (Zinkemagel and Doherty, 1974), 
and furthermore, the protein antigen is typically processed to a small peptide 
prior to its presentation to TcR.
The primary function of B cells is to produce antibodies against a vast 
array of antigenic substances potentially harmful to the body, whereas, T-cells 
regulate secretion of antibodies and limit the probability of an autoimmune 
response. The strategy evolved to allow higher vertebrates to produce such a 
large spectrum of antibodies is the generation of millions of clonally diverse B 
cells, each of which produces antibody molecules consisting of paired heavy 
and light chains and having unique antigen binding specificity. Once generated, 
B cells bearing their antibody receptors are seeded via the blood stream to 
lymphoid tissues in strategic locations throughout the body, such as the spleen, 
lymph nodes and specialised areas along the intestine. In these 
microenvironments, B cells may encounter the foreign (or self) antigens, which 
they recognise via their cell surface antibody receptor.
1.2. B-cell generation.
Vertebrates can produce a humoral immune response to a large number 
of different foreign antigens because B lymphocytes are able to synthesise
21
immunoglobulins having many different antigen binding specificities. The 
generation of B lymphocytes from stem cells occurs through an ordered 
program of immunoglobulin (Ig) variable (V) region gene rearrangement and 
subsequent selection of combinatorial variants. As a result, each newborn B 
cell expresses a particular pair of heavy (H) and light (L, k and A,) chain V 
region (Alt, e ta l, 1987; Tonegawa, 1983) each containing V and constant (C) 
genes. The diversity in structure of variable regions, the antigen binding 
domains of immunoglobulins, results in diversity of antigen binding specificity. 
Each resting B cell in the lymphocyte population expresses an Ig molecule with 
a single V region structure, and thus a single or limited number of binding 
spedficities, as cell surface receptors. A subset of these cells are stimulated to 
grow and secrete antibody at the onset of an immune response partly as a 
result of clonal selection by receptor-bound antigen.
When the haemopoietic stem cells subsequently migrate to the bone 
marrow, this tissue becomes the permanent site of B-cell production (Osmond, 
1986). B-lineage cells can be divided into three general stages of differentiation 
represented by pre-B cells, B cells and plasma cells. As a lymphoid stem cell 
differentiates to a pre-B cell, there is a p H chain gene rearrangement, 
transcription, translation, and expression of cytoplasmic p H chains in 
association with a surrogate light chain (X5+V pre-B) (Karasyuama a l, 
1990). Only after both chains are expressed in the cytoplasm will a complete 
antibody molecule appear on the cell surface. In each antibody forming cell, 
only one heavy chain and one light chain V region are productively rearranged 
and expressed (allelic exclusion). The immature B cell develops to a B cell that 
co-expresses IgM and IgD on the B lymphocyte surface (Coding, 1982). Up to 
this stage, B-lymphocyte development is antigen independent. Maturation 
beyond the B cell stage is thought to require activation by mitogen or an 
appropriate combination of antigen, T cells or T cell factors, and macrophages 
(McKenzie and Potter, 1979). Following encounter with antigen and activated
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T cells, B-cells migrate to B-cell follicles where they interact with follicular 
dendritic cells (FDC). FDC specialise in binding antibody-antigen immune 
complexes and in inducing B-cell proliferation and differentiation. This 
interaction leads to the formation of a finely structured germinal centre. B-cell 
proliferation and differentiation leads to dark zone formation in the germinal 
centre, followed by the formation of the light zone (MàcLennan, et a l, 1992). 
V genes undergo somatic mutation to increase affinity for antigen within days 
of antigenic stimulation and only during germinal centre formation. It was 
suggested (MacLennan and Gray, 1986) that cells are selected in germinal 
centres on the basis of their ability to receive signals dependent on interaction 
with antigen held on FDC. Cells which do not receive signals die by apoptosis. 
The B cell expressing high affinity antibody can follow a number of pathways: 
it can terminally differentiate into an immunoglobulin M (IgM) secreting 
plasma cell, it can switch (Shimizu and Honjo, 1984) its fully assembled V 
region to a downstream C-region gene to express and secrete a new class of 
antibody with a different C region that is associated with a different effector 
function (Winkelhake, 1978), or it can become a memory cell that can 
recognise and be restimulated by the same antigen. The antibodies made by an 
individual plasma cell are of single specificity and a single isotype. To 
appreciate the functional aspects, it is important to understand the basic 
structure of the antibody molecule.
1.3. The antibody molecule
An antibody molecule of the IgG subclass appears as a Y shaped object 
in the electron microscope that consists of two identical heavy (H) and light 
(L) chains that are disulphide-linked to form a bivalent H2L2 molecule (fig 1). 
The two arms of the Y (Fab fi-agments) can be cleaved by proteolysis and 
retain the capacity to interact with antigen. The amino terminal end of each
Antigen Binding
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VH PDPi
VH
JCDR2
CDR3 JH VL
VL
CHICH1CDR1 VL
CDR2
CDR3
- S  s - CL
CL
CH2CH2
Effector Function
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H and L chain is encoded by a variable (V) region gene and the carboxy 
terminal end is encoded by a constant (C) region gene. The V-region domain 
contains three areas of exceptional amino acid sequence variability called 
complementarity-determining regions (CDRs) which are the sites for antigen 
contact (Wu and Kabat, 1970). Surrounding the CDRs are areas of less 
sequence variability called framework regions. Because the CDRs are loop 
structures, they are more likely to be regions of high flexibility which may be 
an important feature of antigen binding (Tainer, et a l, 1985).
The V-region domains are encoded by a series of smaller genetic 
elements designated variable (V h), diversity (D h ), and joining (Jh) for the 
heavy chains and Vl and Jl for the light chains. Each genetic element is part of 
a larger linkage group, and those encoding the murine heavy and both light 
chains, kappa (k) and lambda (X) V regions are located on different 
chromosomes (Alzari, et a l, 1988). Each group of genetic elements is 
separated in the germ-line configuration , and for the heavy chain, there are 
100 to 1000 Vh (Tonegawa, 1983), approximately 12 D and 4 J genetic 
elements. In mouse, the k  light chain has more than 100 V and 5 J genetic 
elements, one of which, Jk3, is a pseudogene. The formation of a complete V 
region occurs by a site-specific recombination mechanism (Tonegawa, 1983). 
Before each of the many antibodies can be presented on the surface of 
individual antibody-forming B cells, the V region genes are rearranged and 
brought into close proximity with their respective C-region genes, a process 
that triggers their expression. Processing of pre-mRNA then joins the V and C- 
region genes to produce m-RNA that is translated into the complete 
polypeptide chains. The heavy chain genes rearrange and are expressed first in 
the cytoplasm of the cell along with the Cp-region gene, and this is followed by 
the rearrangement and expression of a light chain. In each antibody-forming 
cell, only one heavy chain and one light chain V region are productively 
rearranged and expressed, a phenomenon called allelic exclusion. Since any V
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can join to any (D), J and C, there are potentially over 800 different kappa 
chains and over 8000 possible heavy chains that can be formed, and with a 
combination of any L to any H chain, a potential 6.4 million different possible 
antibodies (excluding junctional region diversity and somatic mutation) (Alt, et 
a i, 1982; Paige, etal., 1978).
The diversity of antibody specificities is contributed by a variety of 
factors, including the multiplicity of distinct germ-line Vh and Vl sequences 
that encode different primary amino-acid sequences, the combinatorial 
assortment of the multiple V, D, and J segments, mechanisms that modify the 
coding capacity of the regions where these segments are joined (thus, 
modifying CDR 3), somatic mutational mechanisms that modify the coding 
capacity of the fully assembled variable region gene (Rajewsky, et a i, 1987), 
and the combinatorial association of unique heavy and light chains to form the 
complete antibody. Together, these factors permit the generation of a nearly 
limitless variety of different antibody specificities (Tonegawa, 1983).
1.4. Mechanism of Immunoglobulin V-region assembly
The rearrangement of V region genes is a highly regulated process 
V(D)J recombination appears to be directed by sequence information contained 
within the intervening segments that are deleted or displaced during the 
formation of a functional antigen-binding exon. Sequences at the end of these 
gene segments are known as recombination signal sequences (RSS). An RSS 
contains a conserved palindromic heptanucleotide sequence CACAGTG 
separated by a spacer of 12 or 23 bp fi"om a less conserved AT rich nonameric 
sequence ACAAAAACC.
Asymmetry of these spacers guides V gene segment assembly such that 
only segments with different size spacers are juxtaposed (12/23 rule). Twenty- 
three base spacers immediately flanking 5’ of Vh and 3* of Jh genes, and 12 
base spacers of both 5 and 3 of D r ensures D joins to J, then V to DJ. Direct
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V-J joining is not observed at a significant frequency due to 12/32 rule, and 
although V-D (without J) is possible by this rule, this pairing is not found at a 
significant fi'equency relative to V-DJ.
Several years ago, the recombination activating genes, RAGl and 
RAG2, were identified (Oettinger, et a l, 1990). Mice lacking RAG-1 and 
RAG-2 suffered fi*om severe immunodeficiency disease due to their inability to 
initiate VDJ recombination in developing T and B cells (Oettinger, et a i, 
1990). Elimination of either RAG-1 or RAG-2 fi’om the germ line of a mouse 
is sufficient to eliminate completely recombination of both immunoglobulin and 
TcR genes and prevents the development of B and T lymphocytes 
(Mombaens, et a l, 1992). Thus, either RAG-1 and RAG-2 are lymphoid 
specific components of the V(D)J recombinase or induce the expression of 
genes necessary for carrying out V(D)J recombination. Several other gene 
products have also been shown to be involved in V(D)J recombination. These 
include the XRCC5 protein, which also plays a role in DNA repair in response 
to DNA damage (Taccioli, et a l, 1994), and the SCID protein, which has been 
shown to be involved in both double-strand break repair and coding joint 
formation (Fulop and Phillips, 1990).
Once VDJ recombination has occurred, these join to the C region gene, 
initially to the most Jh proximal which is Cp, so during early B-cell 
develoment, the cells always express surface membrane IgM which facilitates 
light chain gene assembly and expression. It was suggested that membrane p (p 
m) expressed by pre B cells in association with surrogate L chains X5 and 
VpreB on the preB cell surface may generate a signal that activates Vk 
rearrangement. This complex in association with Iga and IgP transmembrane 
heterodimers couples surface Ig to signal transduction machinery in the cell. 
Cross-linking the complex induces Ca  ^ mobilisation and p m generates the
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regulatory signal for suppression of further Vh rearrangement and enhancement 
of Ig K locus rearrangement.
PreB cells synthesise p H chains but not k or A. L chains and therefore 
complete IgM molecules are not expressed, p chains are retained in the 
endoplasmic reticulum (ER) where they bind to the retention protein BiP, a 78 
kDa glucose-regulated protein, and therefore cannot migrate to the Golgi to be 
exported. When L chains are synthesised in sufficient amounts to displace BiP, 
IgM moves to the Golgi and undergoes glycosylation, processing and export to 
the cell surface.
1.5. Affinity maturation 
1.5.1.Somatic hypermutation.
The events leading to the generation of memory B cells occur in the 
germinal centre and include somatic mutation, clonal expansion, Ag-driven 
selection, and isotype switching (Berek, 1993; Berek, et a l, 1991; Kroese, et 
û r / . ,  1987; Nossal, 1992) and are associated with increase in affinity of 
antibodies produced.
After the Ig repertoire is created, following maturation of B 
lymphocytes and Ig gene rearrangement in the germinal centre, B cells undergo 
fiirther diversification of the rearranged V(D)J genes via the process of somatic 
hypermutation followed by the selection of high-afifinity variants (Griffiths, et 
a l, 1984) which are later on expanded. B cells expressing low affinity 
receptors are not selected and die through apoptosis (Liu, et a l, 1989).
Somatic hypermutation plays a central role in antibody affimty 
maturation and is in large part responsible for the production of the secondary 
repertoire. Sequencing of the V genes from hybridomas producing antigen- 
specific antibody revealed two types of changes during the immune response. 
First, immunoglobulin genes are usually expressed in mutated form with the 
degree of mutation increasing during the course of response. For example.
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following immunisation with 2-phenyl-5-oxazolone, there were essentially no 
mutations at day 7 (following primary immunisation), but the extent of 
mutation was such that by day 14, no identical sequences were found (Berek 
and Milsiein, 1987). Second, the repertoire of germline V genes used in the 
response shifted. Thus, at day 7 and to a lesser extent at day 14, a Vh 
O x I/V kO x I gene combination predominated. Following secondary 
immunisation, Vh/Vl gene combinations other than Vh Oxl/VxOxl were 
found with greater frequency.
In the C57 BL/6 antibody response against nitrophenyl (NP), antibodies 
using heavy chain Vh 186.2 and light chain VA.1 genes dominate the early 
primary response. Somatic mutation in clonotypes was observed as early as six 
days after primary NP immunisation (Cumano and Rajewsky, 1986; Yokochi, 
et a l, 1982). The mutational change in hypervariable region CDRl of 
tryptophan at position 33 to leucine increases antibody affinity for NP ten fold. 
This change was found in 75% of late primary and B memory clones. There 
was no further selection after somatic mutation as affinity increasing mutations 
emerged by the end of the second week. Early somatic mutation, in the first 
week (CDR3 usage) is restricted to the germinal centre pathway of 
development, but early ab secreting cells take a different, independent pathway 
of development and a secondary selection event occurs at the bifurcation of 
these two paths in vivo (Berek, et a l, 1991).
Extensive analysis of somatic mutations in antibodies has revealed that 
mutations are largely confined to the variable domains specifically in the CDRs 
(Berek and Milstein, 1987), and rarely found in the constant domains 
(Gearhart and Bogenhagen, 1983). Some residues are frequently targeted (hot 
spots). Mutations largely occur over a region of one to two kilobases, around 
the rearranged V-J segments and the mutation domain extends from a 5’ site 
within the leader intron (Both, et a l, 1990).
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1.5.2. Ig Class Switching.
Antibodies can be classified according to their heavy-chain constant 
regions into eight (for mice) or nine (for humans) classes or serological 
isotypes. Ig class switching can take place at any time during B-cell 
proliferation. At two differentiation stages, however, switching occurs at 
remarkable high fi-equencies, namely, (a) at the formation of naive B cells with 
a particular switch fi-om IgM to IgM+IgD, and (b) at activation of B cells with 
a switch fi-om IgM to IgG, IgA or IgE expression (Esser and Radbruch, 1990) 
because of the expression of a different heavy-chain constant region (C h). Cp 
is the first Ch gene expressed upon generation of a functional V h DJh gene. 
After the assembly of an immunoglobulin light chain, VlJl gene, the complete 
IgM molecule is then presented on the cell surface of the B cell. The next step 
is expression of both Cp and CÔ with the same VhDJh gene and is achieved by 
a combination of differential termination of transcription and differential 
splicing of transcripts of the Vh -D-Jn-Cp-CÔ regions (Tucker, 1985). Upon 
activation by antigen, resting B cells proliferate, differentiate into 
immunoglobulin secreting plasma cells and memory cells, and at a high 
frequency, switch to expression of Gy, Cs, or Ca genes to make IgG, IgE and 
IgA. The IgG class comprises four subclasses, IgGl, IgG2a, IgG2b, and IgG3 
in mouse; IgGl, IgG2, IgG3 and IgG4 in humans.
The isotype pattern varies according to the mode of B-cell activation, 
which is dependent on the antigen, route of immunisation, regulatory cells 
involved and genetic background of the responder (Hocart, et a i, 1989; Slack,
1985). Coutelier et al, in 1987 analysed the isotype distribution in antiviral 
immune responses using a panel of murine DNA and RNA viruses. In most 
cases IgG2a was produced in a 10 to 100 fold excess over IgGl (Coutelier, et 
a l, 1987) and this is now known to be due to the contribution of regulatory 
(ThI type) T cells that preferentially secrete y-interferon (to be discussed later).
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1.6.Cellular Immune Responses
1.6.l.T cell specificity and repertoire.
There are significant differences between B-cell and T-cell recognition 
of antigen. While B cells bind free antigen, T cells bind antigen that has been 
internally processed by proteolysis and re-expressed on the cell surface in 
association with molecules encoded by the major histocompatibility complex 
(MHC). However, it is important to note that T and B lymphocytes are 
complementary parts of a larger defence system, and that in particular, B cells, 
having encountered an antigen appropriate to their surface immunoglobulin, 
usually need T cell signals (in the form of lymphokines) before they can 
differentiate into plasma cells and secrete antibodies. Thus, in at least this way, 
the recognition systems are linked and interdependent.
The genes encoding MHC molecules are highly polymorphic, and in 
general, a T cell will not respond to its antigenic peptide bound by the wrong 
alleie of MHC (MHC restriction). MHC molecules can be subdivided into two 
classes; MHC class I molecules are found on the surface of all somatic cells, 
while MHC class n  molecules are expressed selectively on the surfaces of 
antigen presenting cells (APCs), such as B cells and macrophages. T cells can 
be subdivided into two separate functional categories: cytotoxic T lymphocytes 
(CTLs) bearing CD8 molecules recognise antigen in association with MHC 
class I and T helper cells (Th) bearing CD4 molecules recognise antigen in 
association with class H. Precursor T cells bearing receptors which can bind 
well to self peptides on self MHC alleles die in the thymus, a process called 
negative selection which leads to self tolerance.
T cell recognition of antigen in association with MHC is mediated by a 
single T-cell receptor (TcR) (Yague, et a l, 1985). TcR is a heterodimer made 
of two chains, predominantly a  and P assembled in an antibody-like fashion, 
however, during ontogeny of the immune system, T cell receptors expressing y
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and ô chains are also found. The function of the y:0 heterodimer is unknown, 
whereas TcR a:p appears to be responsible for the specificity of all cytotoxic 
and T helper cells. Each polypeptide consists of seven regions, an N-terminal 
hydrophobic leader region of 18-29 amino acids, a membrane distal V segment 
of 88-98 amino acids, a J region of 14-21 amino acids, C region of 87-133 
amino acids, a connecting peptide of variable length, a transmembrane region 
of 20-24 amino acids and a small cytoplasmic tail of 5-12 amino acids. TcR 
(VDJ) p and (VJ)& are homologous to Ig V regions, and TcR C « and Cp are 
homologous to Ig C regions. Although the exact number of hypervariable 
regions in TcR sequence is controversial, diversity is clearly evident in the 
regions equivalent to the three classic immunoglobulin hypervariable regions.
Like the Ig loci, the TcR genes are divided into an array of 
interchangeable coding segments scattered over large tracts of chromosomal 
DNA These genes are actually composed of two parts: a variable gene and a 
constant gene. The variable gene is composed of either two (V and J) or three 
(V,D and J) gene segments and each gene family has multiple V and J gene 
segments and one to three constant genes. The V,D, and J gene segments are 
separated in the germ line and are brought together by DNA rearrangement 
during T lymphocyte differentiation to form the complete V gene (Chien, et a i,
1984). An interesting feature of T cell receptor gene organisation is the relative 
abundance of J region gene segments in TcR a  and TcR P genes and a relative 
scarcity o f V region. The net result of this is to greatly increase the amount of 
potential diversity in the amino acids encoded by the V-J interface in TcR 
versus the equivalent region in immunoglobulins and to significantly decrease 
the diversity e x p re ss  in the remainder of the V region heterodimer.
Diversity of TcR expression is generated in much the same way as for 
immunoglobulins, through the combinatorial joining of DNA segments and the 
variable addition of nucleotides at junctions (Davis and Bjorkman, 1988).
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Alignment of TcR sequences during T-cell ontogeny in the thymus, leads to 
defined hypervariable regions, much in the same way as with antibodies, with 
one possible major difference: the TcR a  and P sequences display only one 
well-clustered region of hypervariable residues (equivalent to CDR 3) 
(Bougueleret and Claverie, 1987). TcR heterodimers a , P, y ,6 are usually 
found associated with other molecules in the CD3 complex, which includes at 
least four additional membrane-spanning polypeptide chains (Clevers, et a l,
1988). In addition, accessory molecules such as CD4 and CD8 participate in 
the interaction between T cells and APCs and determine restriction to a given 
MHC class with CD4 T cells predominantly recognising MHC class II while 
CDS T cells largely recognise MHC class I.
1.6.2. The structure and function of MHC molecules.
MHC molecules are polymorphic cell surface glycoproteins that occur 
in two distinct forms: class I MHC molecules (H-2 in mice, HLA-A, B, C in 
humans) consist of a glycosylated heavy chain of about 45kDa, which spans 
the cell membrane, associated non-covalently with a non-polymorphic, 
nonglycosylated, 12kDa light chain called P2-microglobulin, MHC Class II (la 
in mice, HLA-D in humans) are made of two covalently linked polymorphic 
chains, a  and P, that both span the cell membrane and associate as a 
heterodimer.
MHC class n  molecules present antigenic peptides to CD4 positive Th 
cells (Unanue, 1984). The peptides bound to class II are derived mainly from 
proteins that have entered the endocytic pathway. MHC class I, on the other 
hand, binds and present those peptides to CD8 positive CTLs that are derived 
by proteolysis in the cytoplasm (Townsend, et a l, 1989). Presentation of 
foreign antigens to helper T cells requires co-ordination of both the 
biosynthetic and endocytic pathways within specialised APCs. The endocytic 
pathway generates and delivers antigenic peptides to the MHC class II
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molecule (Brodsky, 1990). Class H molecules assemble in the endoplasmic 
reticulum with a third protein, invariant chain (li) (Germain, 1986; Long,
1989). li blocks binding of endogenous antigens to the class II molecules and 
stabilises the unoccupied aJ 0 dimers while targeting them through the 
biosynthetic pathway to an endosomal compartment (Townsend, et a i, 1989). 
After removal of li in the acidic and proteolytic environment of the endosomal 
compartment, the class II molecules bind peptides. Peptide-loaded class II 
complexes are then transported to the cell surface for recognition by T cells.
The peptides which bind MHC class I molecules are derived from 
proteins that are expressed within the cell. Peptides of 8-10 residues are 
transported from the cytosol into the endoplasmic reticulum (ER) by the 
MHC-encoded TAP (transporter-associated with antigen processing) proteins, 
TAP-1 and TAP-2 (Schumacher, et a l, 1994). Loosely assembled class I a  
chains and pz-microglobulin are retained in the ER until peptide binding 
induces a conformational alteration, resulting in their rapid transport through 
the Golgi complex to the cell surface.
In addition to determining antigen presentation during an immune 
response, MHC molecules also play an important role in driving thymocyte 
development. MHC molecules on thymus epithelial cells select both positively 
and negatively for maturation and export to the peripheral lymphoid organs for 
T cell bearing receptors that will be able to react to a foreign peptide 
presented by the same MHC molecule (Von Boehmer, 1994).
1.6.3. Functional différences between Thl and Th2 cells.
Activated T cells play a fundamental role in the regulation of humoral 
and cellular immune responses by both cell / cell contact and by secreted 
lymphokines. Differential production of cytokines by helper T cells (Th) during 
an immune response is the basis for distinguishing two subtypes Thl and Th2 
which are functionally different. Thl responses in mice are characterised by
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substantial interleukin 2 (IL-2) and y-interferon (IFN-y) release. Thl responses 
predominate in viral infection resulting in activation of macrophages to kill 
intracellular parasites, in delayed-type hypersensitivity (DTH), and IgG2a, but 
no IgE synthesis, while responses to bacteria and parasites for the most part 
involve Th2 cells and the release of IL-4 and EL-5. The Th2 responses recruit 
IgGl and IgE responses.
Th cell clones do not constitutively secrete lymphokines but are 
dependent upon antigen or mitogenic stimulation to do so (Mosmann and 
Coffinan, 1989). TcR ligation by either anti-TcR abs or antigen/ class II results 
in the induction of lymphokine secretion which in turn induces the proliferation 
and differentiation ofB cells (Lichtman, et a i, 1987).
1.6.4. Cellular Interactions in the Humoral Immune response.
Specific recognition of foreign antigen by cell surface immunoglobulin 
(Ig) and consequent cross-linking induces B cells to proliferate and 
differentiate into either plasma cells, which produce soluble immunoglobulin, 
or into memory B cells which can respond to subsequent encounter with the 
same antigen The proliferation and differentiation of resting B cells requires 
contact dependent, antigen specific, major histocompatibility complex (MHC) 
class n  restricted interaction with Th cells. In contrast, the growth and 
differentiation of activated or large B cells is mainly mediated by lymphokines 
that act in an antigen non-specific, genetically unrestricted fashion (Noelle,
1992). Stimulation of T lymphocytes in turn requires both TcR engagement 
(including the CD4 and CD8 co-receptors) with an antigenic-peptide MHC 
complex and an additional, contact dependent, costimulatory signal delivered 
by an antigen presenting cell (APC) (Schwartz, 1990). Costimulation is 
potentially mediated by a large set of non polymorphic cell surface molecules 
interacting with counter-receptors expressed by T cells.
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CD40 and CD80, both interacting with T cell specific CD40L (gp39), 
CD28 and/or CTLA-4 represent the best characterised costimulatory molecules 
expressed by APC (Fig 2). Once active, the T cells in turn promote B-cell 
activation, both by releasing T-cell-derived cytokines such as IL-2 and IFN-y 
by Thl cells and IL-4 and IL-5 by Th2 cells as well as by direct intercellular 
contact (MacLennan, e ta l, 1992).
CD40, a surface glycoprotein is related to the receptors for tumor 
necrosis factor-a (TNF-a) and is expressed on pre-B cells, mature B cells and 
certain accessory cells. Cross-linking CD40 promotes B cell proliferation 
(Clark and Lane, 1991), prevents apoptosis of germinal centre B cells and 
promotes immunoglobulin class switching (Jabara, et a l, 1990). When the 
CD40-CD40L interaction is blocked in vitro with soluble CD40 or monoclonal 
antibodies to CD40L (gp39), B cells cannot proliferate or produce 
immunoglobulin in response to T-cell signals.
Recently, the gene encoding CD40L has been shown to be defective in 
patients with hyper-IgM syndrome. Although these patients have IgM- 
producing B cells, they do not form germinal centres in response to foreign 
antigen. Their B cells are capable of switching fi-om IgM to IgG or IgE 
production in vitro when exposed to IL-4 and monoclonal antibodies against 
CD40 , but they do not switch immunoglobulin class in vivo (Hill and Chapel, 
1993). T cells and CD40L-CD40 interactions are thus essential.
Whereas the CD40-CD40L interaction enables the B cell to respond to 
an activated T cell, the interaction between CD80 and CD28 allows peripheral 
T cells to respond to an activated B cell by dividing and producing cytokines 
required for T cell differentiation. Of the ligands for the CD80 family, CD28 is 
found on resting and activated T cells whereas, CTLA-4 is found only on 
activated T cells. The binding of CD80 to CD28 on T cells previously 
stimulated through their antigen receptors increases IL-2 production and T-cell
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proliferation (Linsley, et a l, 1991). Interference with this signal in vitro can 
block T-cell proliferation and B cell maturation induced by T-cell cytokines. 
CD80 expression is induced or stimulated after cross-linking MHC class II 
with monoclonal antibodies or during autoreactive T-cell interaction with B 
cells (Nabavi, et a i, 1992). This cross-linking may thus induce CD80 
expression in B cells so that CD80 can, in turn, signal to the T cell via CD28. It 
has been shown that simultaneous signalling through TcR and CD28 results in 
the synergistic activation of two mitogen-activated protein kinases, JNKl and 
JNK2(Su,e/a/., 1994).
The CD40L-CD40 and CD28/CTLA-4-CD80 ligand pairs are not the 
only means by which T cells and B cells interact. The CDl la/18-CD54 ligand 
pair is also likely to play a part; an active form of CDl la/18 is rapidly induced 
on crosslinking the T cell receptor complex (Dustin and Springer, 1989). 
Antigen-specific T-cell activation rapidly induces a CDlla/18-CD54- 
dependent signal to the antigen presenting B cells and crosslinking CD40 on B 
cells promotes allogeneic T cell proliferation via CDlla/18-CD54-dependent 
interactions (Barrett, e ta l, 1991).
Patients with leukocyte adhesion defects do not express CDl la/18 on 
their T or B cells. They make both IgM and IgG antibodies in response to 
specific antigen, but have depressed antibody titres, indicating that their 
production of memory B cells may be impaired (Ochs, et a l, 1993).
A number of surface molecules (e.g. CD 19 and CD22) are associated 
with cell-surface IgM and are rapidly phosphorylated on tyrosine residues after 
they become cross-linked (Clark, 1993). CD22 may be required for normal 
signalling, as intracellular calcium is not elevated from cross-linking surface 
immunoglobulin in CD22-negative B cells. CD 19 is expressed on B cells 
throughout their maturation. It interacts with various molecules on other B 
cells, including the receptor for Cd3 component of complement, CD21/Cd2,
38
indicating that it may facilitate a complement-mediated signalling pathway. 
When cross-linked, CD 19 induces calcium mobilisation in both pre-B and 
mature B cells.
Antigen specific T-cell activation is dependent on interactions between 
T cells and APCs, specifically B cells. Once active, the T cells in turn promote 
B-cell activation, both by releasing T-cell-derived cytokines such as IL-2 and 
IFN-y (by Thl cells) and IL-4 and IL-5 (by Th 2) and by direct intercellular 
contact (MacLennan, et a l, 1992). T cells play an essential role not only in the 
activation of resting B cells, but also in isotype switching (Kong and Morse, 
1976) and affinity maturation of the antibody response; The more T- 
independent the response, the poorer the qffinity maturation (a particularly 
relevant feature for the subject matter of this thesis). T cells also play a major 
role in generating memory B cells which can respond more effectively to 
subsequent challenge with antigen (Feldbush, et a l, 1986). Once B cells have 
been activated by first T cells and later by follicular dendritic cells, they express 
an array of surface receptors, specifically CD40 and CD80, and can present 
antigen to T cells effectively.
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1.7. Viral Immune Evasion Strategies
Latent and / or persistent infections are part of the life style of many 
viruses. This capacity to maintain a long-term relationship with the host 
presupposes viral mechanisms for circumventing antiviral defences. Viruses 
that infect vertebrate hosts achieve sustained host-to-host transmission by 
using specific strategies that evade or subvert the consolidated activities of the 
anti-viral immune and inflammatory responses.
Certain RNA viruses, including influenza virus and human 
immunodeficiency virus, escape humoral or cellular immunity by mutating their 
cell surface glycoproteins as a consequence of the error-prone RNA 
polymerase. A strategy particularly common among DNA viruses, which are 
less capable of fi-equent and rapid mutations, is to synthesise proteins that 
modify host immune attack. The larger DNA viruses are of particular interest 
because they encode proteins that are not required for virus replication in 
tissue culture, but instead allow for virus propagation in host tissues that are 
normally visible to the immune and inflammatory systems of the host. Several 
mechanisms have been reported of virus modulation of the host response to 
infection which can be divided into the following categories;
I.7.I. Latency.
Latency is defined as a type of persistent infection in which the viral 
genome is present in the host but infectious virus is not produced except during 
intermittent episodes of reactivation. Viruses that are considered latent evade 
immune responses by hiding in privileged sites or changing patterns of 
cytopathogenicity, growth kinetics or tissue tropism. It is a common feature of 
herpesviruses especially Herpes Simplex virus type 1 (HSV-1),
Cytomegalovirus (CMV), and Epstein-Barr virus (EBV) that acute infection is 
not terminated by clearance of infectious virus and the viral genome but is
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followed by a phase of persistent virus replication which is often confined to a 
particular tissue site.
HSV is a common neurotropic virus which in humans and experimental 
animals establishes latent infection of sensory ganglion neurons. Following 
entry into the host, virus undergoes primary replication in the skin or mucosae. 
The virus then gains access to the distal axon terminals of sensory neurons and 
travels by axonal transport to neuronal cell bodies in sensory ganglia, where 
limited replication may occur and viral gene expression is repressed, leading to 
a latent state. The host immune response curtails viral replication in the ganglia 
and potentially lethal spread to the brain. A primary immune response, 
however, is unable to prevent establishment of latent HSV infection in 
ganglionic neurons. Latent viral genomes existing in a non replicating state are 
reactivated by unknown mechanisms and depending on conditions of local 
immunity, reactivation may result in recurrent skin lesions (Roizman and Sears, 
1987).
Recovery from acute HSV infections requires T cell responses and it 
has been shown that MHC class Il-restricted CD4 T cells are pnmanly 
responsible for clearing HSV from skin, whereas MHC class I restricted 
cytotoxic T cells control HSV replication in the nervous system (Nash, et a i,
1987).
Reactivation of infectious virus fi-om latent viral genomes is the 
initiating event in the pathogenesis of CMV disease during immunodeficiency, 
bone marrow and/ or organ transplantation including liver, kidney, heart and 
lung transplantation (Ho, 1991). In a murine model of CMV latency, the lungs 
were identified as a major site of latent infection, since a high-copy of viral 
genome was detectable in lung tissue even after it was cleared to an 
undetectable level in blood and bone marrow (Balthesen, et a l, 1993). A 
comparison of lungs and the spleen, the previously most thoroughly
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investigated site of murine CMV latency, revealed a 10-fold-higher burden of 
latent viral genome for the lungs.
Activation of B cells causes a switch from latent to lytic EBV infection. 
In latently infected B lymphocytes a specific origin of viral DNA synthesis and 
a set of viral proteins (EBNAs) without known DNA polymerase activity 
appear to be responsible for the limited amplification and maintenance of the 
EBV genome in an episomal state (Yates, et a i, 1985). Two EBV latent 
membr^e proteins (LMP-1 and LMP-2) influence B cell activation and hence 
virus replication. Crosslinking of the B cell surface antigens, such as IgM, 
MHC class II or CD 19, causes signal transduction and an intracellular calcium 
flux that leads to cell activation. This process is downregulated by I.MP-2A, 
probably because of its association with cytoplasmic tyrosine kinases, and 
hence cell activation and progression into lytic replication is restricted. This 
may be an advantage to the virus in the presence of a vigorous antibody 
response that may neutralise the virus infectivity.
Current opinion on AIDS pathogenesis divides the clinical course of 
HIV infection into a latent phase, in which the virus is silent, and a progressive 
phase, in which HIV replication is induced with a rapid loss of CD4 + T cells. 
During this latent or subclinical phase of infection, HIV continues to replicate 
at low levels despite an often vigorous but ineffective host immune response. 
When an individual is infected with HTV, a mixture of related HTV clones is 
transmitted. Cells infected with virulent, high expressing HIV variants are 
selectively eliminated by the uncompromised host imriiune system (Asjo, et a l,
1988). Low virulence variWs may escape immune response because of their 
low-level expression or their monocytotropism (Popovic and Gartner, 1987). It 
has been shown that monocytes, macrophages and dendritic cells can be 
infected with HIV and support HIV replication in vitro and in vivo (Plata, 
1987). First, monocytes-macrophages may be persistently infected and function 
as a reservoir for virus dissemination to lungs and brain (Koenig, et a l, 1988)].
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Second, HIV infection may induce severe defects in the accessory functions of 
monocytes and peripheral blood-derived dendritic cells from symptomatic and 
asymptomatic HTV individuals. Shearer and co workers demonstrated a 
selective loss of T-cell reactivity in asymptomatic HIV-infected individuals 
with respect to both proliferation and generation of cytotoxic T-lymphocytes in 
response to nominal antigen presented by self MHC molecules (Shearer, et a l,
1986).
1.7.2. Immunosupression.
Viruses can perturb the host immune system in general by one of the 
two basic mechanisms: disordered immune regulation may be a direct 
consequence of viral replication in immunocompetent cells. For e x a m p l e ,  c e l l  
dysfunction due to infection of helper T lymphocytes could lead to 
immunosuppression or the establishment of persistent virus infection could 
involve virus-specific cytotoxic T lymphocytes (CTL). The majority of the 
viruses, e.g. measles virus, undergo restricted infection in unstimulated 
lymphocytes. Productive infection frequently follows mitogenic stimulation. 
With other viruses, e.g. lymphocytic choriomeningitis virus (LCMV), 
r e p l i c a t i o n  is restricted SO that recovery of infectious virus requires 
cocultivation with permissive cells.
As mentioned above, measles virus infection is associated with 
suppression of immune functions both in vivo and in vitro. Infection with 
measles virus (MV) is accompanied by marked and prolonged abnormalities of 
cell mediated immunity (CMI), which contributes to increased susceptibility to 
secondary infections. Destruction of cells infected by measles virus is due to 
positioning in the cell membrane of cleaved fusion protein of the virus. Infected 
adjacent cells form syncytia that cannot survive. Dunng acute infection, 
measles virus replicates in lymphoid tissues. In vivo, sensitisation and
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expression of delayed-type hypersensitivity (DTH) responses are inhibited for 
several weeks after acute measles virus infection.
The loss of delayed cutaneous hypersensitivity (DCH) to tuberculin 
antigen during measles virus infection was first described in 1908 by Von 
Pirque and has been shown both during natural infection and after live 
attenuated measles virus immunisation. It was observed that the tuberculin skin 
test response of immune individuals was depressed during the time course of 
acute measles virus infection (von Pirquet, 1908).
The effect of measles virus on phytohaemagglutinin (PHA) induced 
stimulation of human peripheral blood mononuclear cells was investigated by 
Sullivan et al. It was noted that medium which had several days contact with 
uninfected monolayers as well as unpurified MV preparations produced 
significant inhibition of ^-thymidine incorporation by PHA-stimulated 
lymphocytes. When partially purified MV preparation was used, marked 
inhibition was observed. Both T and B lymphocytes taken fi-om the peripheral 
blood during natural infection express viral antigen after mitogenic stimulation 
in vitro (Sullivan, et al, 1975).
As with other viruses that disturb CMI such as HIV, monocytes and 
macrophages are prime targets of MV in natural infection (Esolen, et a l,
1993), which are thought to be principal IL-12 producing cells in vivo. IL-12 is 
crucial to the development of CMI, being a potent inducer of IFN-y fi-om T 
and NK cells, required for the development of Thl responses and necessary for 
DTH responses. It was proposed that one of the mechanisms of 
immunosuppression by MV might be down regulation of IL-12 production 
(Karp, et a l, 1996). This was demonstrated by infecting human moncytes with 
MV, followed by stimulation with bacterial antigens which resulted in down- 
regulation of IL-12 induction.
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Retroviruses of murine, avian, feline and human origin are 
immunosuppressive as well as oncogenic in their hosts. In several experimental 
models with C-type retroviruses, virions cause immunosuppression as well as 
neoplasms in a dose dependent manner Since immune mechanisms may limit 
the development or spread of cancer, clinically apparent tumours may develop 
when transformed cells acquire the means to escape host immunological 
defence mechanisms. Studies in the murine and feline retrovirus systems 
suggest that the 15,000-dalton envelope protein (pl5E) of the virion may 
contribute to immune suppression by interfering with normal lymphocyte 
function. It was reported that a partially purified 15-kd structural protein of 
FeLV inhibited the proliferation of feline lymphocytes induced by concanavalin 
A (Con A) (Mathes, et a i, 1978). The inhibition was dose dependent and 
occurred when the protein was added as late as day 3 of a 4 day culture. In 
contrast, another structural protein of the virus, p27, was not inhibitory. The 
same group also demonstrated that both UV inactivated FeLV and plSE 
suppressed the proliferation of human lymphocytes to Con A (Copelan, et a l, 
1983). Suppression Was not mediated by monocytes, as pre-treated monocytes 
were able to secrete IL-1 and serve as accessory cells when cultured with 
untreated T lymphocytes.
Although the selective loss of CD4+ helper T cells in the relatively later 
stages of HTV infection, is the main mechanism by which HTV induces 
immunodeficiency, it has been claimed that the deficient antigen responsiveness 
of CD4+ lymphocytes from HTV-infected individuals is due in part to gp 120- 
induced inhibition of CD4 function (Diamond, et a l, 1988). gpl20 binds to 
CD4 (the receptor for HTV-l) with high affinity thereby facilitating entry of 
the virus into the cell and syncytium formation between infected and uninfected 
cells.
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1.7.3. Down-rcgulation of MHC expression.
Viral peptides from within infected cells are presented on the cell 
surface in association with MHC class I Cells bearing such complexes are 
recognised and lysed by cytotoxic T cells (CTL). CD8+ T cells that recognise 
peptides derived from the viral proteins synthesised in the cytoplasm of the 
infected cells are considered, in certain quarters, to play an important role in 
antiviral defence. However, viruses like adenoviruses, CMV and HSV have 
found means to interfere with immune recognition by down-regulation of MHC 
class I.
Human cytomegalovirus (HCMV) is a ubiquitous pathogen that 
persists in the host and can cause severe disease in immunocompromised 
individuals or the foetus. Analysis of the nucleotide sequence of the virus 
genome has revealed the presence of an open reading frame whose translated 
product has homology with the heavy chain of MHC class I molecules of 
higher eukaryotes (Beck and Barrell, 1988). The observed sequence homology 
was given additional significance by another observation that HCMV virions 
can bind 02 microglobulin (02m), the light chain of MHC class I (McKeating, 
et a l, 1987). Browne, in 1990 did a notable experiment by expressing both the 
HCMV class I homologue and the human 02m gene in recombinant vaccinia 
virus and showed that in recombinant-vaccinia-infected cells, no synthesis of 
mature cellular class I occurred, while. mRNA levels were unaltered (Browne, 
et a l, 1990). Thus, HCMV may evade immune recognition by preventing the 
maturatiori of host class I molecules and rendering the infected cells 
unrecognisable by cytotoxic T cells.
A similar mechanism of decrease in MHC class I expression is used by 
adenovirus 2; the E3-gene-encoded 19kDa protein of Ad2 binds to class I 
heavy chains and prevents transport to the cell surface, which in turn results in
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reduced recognition and reduced lysis of infected cells by CTLs (Andersson, et 
a i, 1987). Andersson et al., examined the biosynthesis of the complex between 
class I and Ad-2 glycoprotein E19 in adenovirus-infected HeLa cells by 
immunoprécipitation and SDS-gel electrophoresis. At 2 hours after infection, 
small amounts of E19 were already co-precipitated with MHC class I heavy 
chains and 02 microglobulin. Later on larger amounts of the E19 were found 
bound to class I, as evidenced by the antibodies against class I, whereas, 
antibodies against E19 protein bound only minor amounts of class I heavy 
chains. The rate of class I synthesis did not vary significantly, but while the 
electrophoretic migration of 02 microglobulin remained the same, the mobility 
of the heavy chain increased such that it became identical to that of core­
glycosylated heavy chains derived fi-om infected HeLa cells suggesting that the 
heavy chains, on complex formation with E19 fail to become terminally 
glycosylated. Thus, interference with antigen presentation by means of direct 
protein-protein interaction with MHC is another strategy by which some 
viruses evade immune surveillance.
Herpes Simplex Virus (HSV) also blocks presentation of viral peptides 
to MHC class I restricted T cells. Antigenic peptides are generated in the 
cytoplasm by proteosomes (Rock, et al., 1994) and translocated into the lumen 
of the endoplasmic reticulum (ER) by TAPI and TAP-2 (Townsend and 
Trowsdale, 1993). HSV expresses an immediate early protein, ICP47 which 
lacks a recognisable signal sequence. ICP47 binds to TAP and prevents peptide 
translocation into the ER. By expressing ICP47 in HeLa cells, Fruh et al 
showed that ICP47 efficiently inhibits peptide transport such that nascent class 
I molecules fail to acquire antigenic peptides. Furthermore, ICP47 colocalises 
and physically associates with TAP within the cell (Fruh, et a i, 1995). Thus, 
interference with peptide translocation into the ER is a further mechanism by 
which yiruMS may evade immune recognition.
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1.7.4. Inhibition of Cytokine function.
Cytokines play a fundamental role in the inflammatory and immune 
response to infection and may directly destroy virus-infected cells. Viruses 
have devised an array of strategies to abrogate cytokine fimction. A strategy 
used by some herpes viruses and poxviruses is to encode cytokine receptor (s) 
that bind and sequester the cognate cytokine and prevent it from reaching the 
natural receptor and triggering signal transduction. Poxviruses express 
receptors for interleukin-10 (IL-10), TNF and interferon-y. In each case, the 
protein is secreted from the infected cells and is homologous only to the 
external cytokine-binding domain of the cellular receptor, lacking the 
transmembrane domain and cytoplasmic region.
An EL-10 receptor has been detected in cowpox and many strains of 
vaccinia virus. IL-1 is produced in response to infection and tissue injury. It is 
involved in the regulation of the inflammatory and immune responses and in the 
activation of a broad spectrum of systemic effects that contribute to host 
defence (Dinarello, 1988). Two classes of EL-l receptors have been identified 
that bind both IL -la  and IL-10 with similar affinity (Dower and Urdal, 1987). 
The 80kDa typel IL-1 receptor is found on T cells and fibroblasts, while the 
type n  IL-1 receptor is present on B cells and macrophages. It was reported 
that vaccinia virus BRI5 ORF (open reading frame) is actively transcribed, 
translated, and encodes secretory glycoprotein in the supernatants of vaccinia- 
virus infected cells that functions as a soluble IL-1 receptor. Unlike the 
membranerbound cellular IL-1 receptors (type I and II), which bind IL-1 a, IL- 
10 and the IL-1 receptor antagonist protein, the virus IL-1 receptor binds only 
EL-10, emphasising the importance of this cytokine in poxvius infections and 
suggesting that it can interfere with the immune responses by blocking the 
effects of this cytokine. This was shown in binding experiments to 
radioiodinated ILs and was corroborated in competition assays with unlabeled
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cytokines and by blocking the interaction of the ILs with the natural receptors 
on cells (Alcami and Smith, 1992).
Similarly other poxviruses, notably shope fibroma virus (SFV), 
myxoma virus, and malignant rabbit virus (MRV) encode proteins with 
homologies to cellular receptors for tumor necrosis factor (TNF). TNF is a 
potent cytokine produced mainly by activated macrophages and plays an 
important role in inflammatory, immunoregulatory, proliferative and antiviral 
responses and also synergises with interferons to augment the antiviral state 
(Beutler and Cerami, 1988). The T2 open reading frame of both SFV and 
myxoma virus possesses significant homology to the ligand binding domains of 
the murine and human TNF (a, 0) receptors (Upton, et a l, 1991). TNF- 
binding protein T2 competitively inhibits TNF binding to its cell surface 
receptor. Targeted disruption of both copies of the myxoma T2 gene revealed 
that the absence of T2 expression caused significant attenuation of 
myxomatosis in rabbits (Upton, et a l, 1991). To characterise the T2-TNF 
interaction, myxoma T2 protein and rabbit, mouse and human TNF-a were 
expressed independently fi-om vaccinia virus vectors. Growth of the TNF-a 
expressing cells was significantly attenuated in TNF-hypersensitive cells (L929- 
8 cells), and these cells were rapidly lysed by all three TNF-as. When the 
ability of the myxoma T2 protein to inhibit biological activities of TNF-a was 
assayed, T2 protein protected L929-8 cells were lysed by rabbit but not human 
or mouse TNF-a.
Myxoma virus also expresses an IFN-y receptor that can protect cells 
from the anti-viral effects of IFN. IFN-y is a potent immunomodulatory 
cytokine produced by activated T lymphocytes and functions to combat viral 
infections by inducing anti-viral pathways and by modulating cellular immune 
responses to viral challenge. It also possess the ability to enhance expression of 
MHC class I and II, resulting in an increase of viral antigen presentation, and
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furthermore, IFN-y induces the secretion of the ligand binding domain of the 
low density lipoprotein receptor, which interferes with assembly and budding 
of certain enveloped viruses. Poxviruses were the first viruses found to be 
capable of interrupting the extracellular ligand-dependent triggering of the 
IFN-y receptors, thus preventing signal transduction from an extracellular 
location. M-T7, the most abundantly secreted protein from myxoma virus- 
infected cells, was shown to be expressed in significant amounts as a typical 
poxvirus early gene product, efficiently secreted at early times of infection, and 
to function as a stable inhibitory protein in infected cell supernatants until later 
times of infection. It contains significant sequence similarity to the ligand 
binding domain of the mammalian IFN-y receptors and functions as a soluble 
homologue which can specifically bind and inhibit the biological activities of 
rabbit IFN-y but not human or murine IFN-y (Mossman, et al, 1995).
1.7.5. Intracellular blockade of cytokine synthesis and function.
As well as expressing cytokine receptors, some viruses have also 
developed measures to block the production of mature cytokines and to modify 
the consequences of cytokine-binding to the receptors. Recently, seven distinct 
serine proteinase inhibitor genes have been discovered in the poxvirus genome 
all of which encode proteins belon^g to the superfamily of serine proteinase 
inhibitors (serpins) (Turner, et a i, 1995). Viruses such as vaccinia, cowpox 
and rabbitpox, each encode three known serpins that have been designated 
SPI-1,-2, and-3. Cowpox virus expresses a 38kDa intracellular protein (crmA) 
with sequence similarity to SPI-1 which inhibits the pro-IL-10 converting 
enzyme (ICE) that cleaves the intracellular 30kDa IL-10 precursor into the 
17kDa mature secreted form.
Recombinant BCRFl protein of Epstein Barr virus (EBV) mimics the 
activity of another cytokine Interleukin-10 (IL-10) suggesting its role in the 
interaction with the immune system. IL-10 is produced by Th2 cells and
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inhibits synthesis of cytokines, specifically IFN-y by activated Th-clones. 
Because Thl cells preferentially mediate delayed-type hypersensitivity (DTH) 
and macrophage activation, whereas Th2 cells provide help for B cells, IL-10 
may represent a mechanism whereby Th2 cells can inhibit the effector 
functions of Thl cells. It has been shown that the mature, secreted IL-10 
polypeptide has approximately 70% homology to BCRFl (Baer, et a l, 1984). 
Hsu et al cloned and expressed the BCRFl gene, and demonstrated that the 
expressed BCRFl protein, like IL-10, inhibits IFN-y synthesis by activated 
lymphocytes (Hsu, et a i, 1990).
Human adenoviruses encode three proteins, E3-14.7K, E3-10.4K/ 
14.5, and E1B-19K, that protect virus-infected cells fi"om cytolysis by TNF 
(Wold and Gooding, 1991). Little is known about the mechanism of action of 
these adenoproteins, except that all three act at steps subsequent to TNF 
binding to its receptor
1.7.6. Inhibition of complement cascade.
The complement system consists of more than twenty plasma proteins 
that participate in host defences against infectious agents and may be activated 
in two ways: the classical pathway requires a specific antibody-antigen 
interaction, while the alternative pathway may be activated in the absence of 
antibody by certain antigens, such as bacterial cell wall polysaccharides. Each 
pathway contains a cascade of enzymatic reactions that greatly amplifies the 
original signal and leads to the formation of a membrane attack complex that 
damages the surface membrane of envelope viruses or infected cells. Several 
poxviruses and herpes viruses have evolved defences against it by encoding 
proteins that have amino acid similarity with proteins of the complement 
system.
Inhibition of both classical and alternative pathways of complement 
activation is mediated by the enveloped glycoprotein gC-1 of herpes simplex
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virus. Glycoprotein C-1 binds the C3b fragment of complement component C3 
which is central to both classical and alternative pathways, thus preventing 
both complement-mediated virus neutralisation and cytolysis of virus-infected 
cells (Harris, e ta l, 1990).
Herpes viruses have adopted an additional mechanism to counter 
antibody dependent complement-mediated attack by encoding a pair of 
proteins, gE and gl. These proteins bind the Fc region of IgG by bipolar 
bridging i.e. antibody binding by its Fab end to HSV antigen and by its Fc end 
to the viral Fc receptor. This bipolar bridging of antibody modifies effector 
functions mediated by the Fc region, including antibody-dependent cellular 
cytotoxicity, binding of Clq, and antibody mediated complement-enhanced 
virus neutralisation (Dubin, et al, 1991)...
Vaccinia virus evades the consequences of complement activation by 
encoding two proteins that have four copies of the 60-70 amino acid motif 
called the consensus sequence (SCR) that is typical of complement control 
protein. One of these is a 35-kDa protein (VCP) that is secreted from the 
infected cell and has closest sequence similarity with a human protein C4b. It 
binds to C3b and C4b fragments of the third and fourth complement 
components, blocks activation of both the alternative and classical pathways, 
and protects intracellular virus from complement-mediated neutralisation of 
infectivity (Kotwal, e ta l,  1990). The second protein is present on the surface 
of the virus infected cells and extracellular virus particles.
The immune system, in conjunction with all its effector mechanisms 
aims to recognise and eliminate viruses and virally infected cells. However, the 
above mentioned examples give a clear picture of an array of strategies by 
which viruses perturb immune mechanisms and ensure their survival.
Antigenic variation, a common strategy of immune evasion by RNA 
viruses, has been most extensively studied for influenza virus. Since this is the
NA
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major subject of interest in this thesis, it will be dealt with in the following 
introductory section.
1.8. Influenza Virus
The study of influenza viruses is important because of the mortality 
and widespread morbidity that occurs during an epidemic. It is an enveloped 
animal virus which belongs to the family Orthomyxoviridae and is classified 
into types A, B and C on the basis of the type-specific nucleoprotein and 
matrix protein (Pereria, 1969; Schild, 1972). Type A viruses have been isolated 
fi’om man, birds and a variety of animals, whereas types B and C have only 
been isolated fi’om humans (Easterday, 1975); with the exception of a type C 
isolate fi’om swine (Guo, et a l, 1983).
The antigenic properties of the surface glycoproteins haemagglutinin 
(HA) and neuraminidase (NA) provide a basis for the further classification of 
influenza A viruses: fourteen to fifteen distinct HA and nine NA subtypes have 
been characterised, all of which occur in avian isolates (WHO, 1980). In 
human, there are only three subtypes, H lNl, H2N2 and H3N2. The current 
circulating human strain is HlNl and H3N2. H3N2 was preceded by H2N2, 
prevalent between 1957 and 1968, and the H lNl before that, first isolated 
from humans in 1933 (Laver and Kilboume, 1966; Laver and Webster, 1966).
1.8.1. Structure of the genome.
The genetic information of influenza virus is contained in eight 
segments of single-stranded RNA of negative polarity (Lamb, 1989) all of 
which are needed for infectious virus. The eight RNA segments encode ten 
polypeptides. Segments 1-6 each encode a single structural protein: the 
polymerases (PB2, PBl and PA), HA, nucleoprotein (NP) and NA Two 
polypeptide species are transcribed from each of segments 7 and 8 using
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Fig 3: Diagram of the influenza virus.
Adapted from Oxford and Hockley, 1987.
The viral segmented genome consists of eight strands of negative polarity 
RNA which encode ten different viral proteins including the antigenic 
surface glycoproteins haemagglutinin and neuraminidase. Haemajgglutinin is 
present on the surface as a trimer and neuraminidase as a tetramer. M2 is a 
membrane protein which forms ion channels (Oxford and Hockley, 1987).
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differential splicing to generate transcripts for the structural proteins Ml and 
M2, and the non-structural proteins NSl and NS2, respectively (Lamb and 
Choppin, 1983; Brand and Skehel, 1972) (fig 3).Viral mRNA synthesis is 
catalysed by viral nucleocapsids (Inglis, et a l, 1976) (Plotch, et a l, 1981), 
which consist of individual vRNAs associated with four viral proteins: the 
nucleocapsid (NP) protein and the three P (PBl, PB2, and PA) proteins 
(Inglis, et a l, 1976; Ulmanen, et a l, 1981). The P proteins are responsible for 
viral mRNA synthesis and appear in the form of a complex that start at 3’ ends 
of the vRNA templates and moves down the templates in association with the 
elongating mRNAs during transcription (Braam, et a l, 1983).
1.8.2. Influenza virus replication.
Influenza viruses bind to cells by interacting with membrane receptor 
molecules containing sialic acid (Gottschalk, 1959). Viral entry and membrane 
fusion is mediated through haemagglutinin. Binding of virus particles to their 
receptors is followed by endocytosis after which fusion of virus and endosomal 
membranes at acidic pH occur. The transcription complex released into the cell 
as a result of membrane fusion is transferred to the nucleus by cellular 
processes which recognise signals on the virus proteins similar to those on the 
nuclear proteins o f the cell. The complex consists of five virus proteins PA, 
PBl, NP and MP and eight RNA molecules of the virus genome. The 
transcription complex has two functions; to synthesise the early virus 
messenger RNAs required for virus replication to begin, and to produce the 
complementary RNAs involved as templates in the replication of virus genome 
RNAs.
1.8.3, Influenza vims budding.
Influenza virus contains a lipid membrane that it obtains during 
maturation by budding fi'om the plasma membrane of an infected cell (Wiley,
1985). In early microscopic studies of the maturation of influenza virus in the 
chorioallantoic membrane of infected chicken embryos (Murphy and Bang,
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1952), it was observed that virus budding occurred at the free luminal cell 
surfaces. Similar polarity in enveloped virus maturation has been observed in 
epithelial cells grown in vitro (Rodriguez, Boulan and Sabatini, 1978). 
Monolayers of the epithelial Madin-Darby canine kidney (MDCK) line form 
tight junctions between adjacent cells and exhibit an electrical potential 
between the upper and lower surfaces (Cereijido, et a i, 1978; Leighton, et a l, 
1970; Nfisfeld, et a l, 1976). It has been reported (Rodriguez Boulan and 
Sabatini, 1978) that vesicular stomatitis virus (VSV) buds exclusively from the 
basolateral membranes in these cells, whereas influenza and parainfluenza 
viruses bud exclusively from the free apical surface.
1.8.4. Structure, function, and antigenicity of the Haemagglutinin of 
influenza.
Haemagglutinin is one of the major surface glycoproteins of the 
influenza virus that interacts with neutralising antibodies; alterations in the 
molecule enable the virus to escape immune surveillance and cause epidemics 
of the disease. HA has two functions in virus replication; it binds virus to cell- 
surfece glycoconjugates by recognising terminal sialic acid residues of 
carbohydrate side chains, and, following endocytosis of bound virus, it 
mediates the fusion of the virus and endosomal membranes required for 
transfer of the virus genome-transcriptase complex into the cell (Wiley and 
Skehel, 1987). To better understand why this virus has eluded our control 
efforts, it is necessary to understand the three-dimensional structure and 
function of the HA molecule and the immune responses to this protein.
1.8.5. Structure of Haemagglutinin.
Haemagglutinin (HA) is a horaotrimcr (Wiley, et a l, 1977) and is 
synthesised in the rough endoplasmic reticulum of infected cells as a single 
polypeptide chain (HAO) of around 550 amino acids. During passage to the 
plasma membrane, the molecule is glycosylated in several positions and is 
subsequently cleaved into two disulphide-linked subunits, HAl and HA2 by
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host cell proteases. Bromelain digestion cleaves HA on virus membranes at 
HA2 175 and results in the release of the entire ectodomain (BHA) as a soluble 
trimer (Brand and Skehel, 1972).
The three dimensional structure of X31 B-HA has been determined to 
3Â by X-ray crystallography (Wilson, et a l, 1981). Basically, each monomer 
consists of a globular membrane distal region consisting of HAl on top of an 
elongated stem consisting of all of HA2 and parts of HAl. Residues 63-305 
form the distal globular domain, which contains an eight stranded anti-parallel 
P-sheet and two short a-helices. This framework supports the receptor-binding 
site present in this region. The receptor binding site is a shallow concave 
pocket of highly conserved amino acid residues surrounded by regions that 
vary with changes in antigenicity. The major forces stabilising the 
haemagglutinin's trimeric subunit interactions arise from a triple-stranded 
coiled-coil in the fibrous region of the molecule.
1.8.6. Antibody recognition sites of Influenza HA.
As mentioned earlier, the conserved receptor binding pocket is 
surrounded by highly antigenic regions against which neutralising antibodies 
are directed and resistance to infection correlates with the levels of serum anti- 
HA antibodies (and secretory IgA) which are subtype specific (Dowdle, et a l, 
1973; Hobson, et a l , 1972). The antibody recognition sites have been deduced 
from structural analysis of laboratory escape mutants, selected with 
neutralising monoclonal antibodies in ovo, and differing from the immunising 
virus by one or occasionally two amino acid substitutions in HA molecule 
(Gerhard, et a l, 1981; Laver, et a l, 1979). The molecular locations of these 
substitutions define five antigenically important sites designated as A-E (fig 4) 
corresponding to most surface exposed regions (Caton, et a l, 1982; Gerhard, 
et a l, 1981; Lubeck and Gerhard, 1981; Underwood, 1982; Wiley, et a l, 
1981). Each one of the proposed antigenic sites A, B, C, D and E has
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Fig 4: Schematic representation of an H3 HA monomer, showing major 
antibody binding regions.
Adapted from Skehel et al., 1984 and after Wharton et al., 1989.
The HA monomer consists of disulphide linked HAl (blue) and HA2 (red) 
subunits, both encoded by the HA gene as HAO, and cleaved to HAl and 
HÀ2. The HA spike consists of a globular head region supported on a 
fibrous stem (containing only HA2 residues) anchored to the viral 
membrane at the base of the molecule. The globular head region, consisting 
mainly of HAl residues, houses the receptor binding site at the trimer 
interface, to the right of the molecule (antigenic site D) and the major 
antigenic sites A-E. Carbohydrate is shown in green (Skehel et al., 1984; 
Wharton, etal, 1989).
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Fig 5: Structure of the receptor binding pocket of the HA molecule (Weis, 
e ia l, 1988).
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1.8.7. Structure of the receptor-binding pocket
The HA of the influenza virus is responsible for binding the virus to 
cell-surface sialic acid receptors during infection. The region of the 
haemagglutinin involved in receptor binding has been deduced from 
crystallographic studies to involve a shallow, concave pocket of several highly 
conserved amino acid residues at its membrane distal surface (Weis, et a i, 
1988).While changes have occurred all around the receptor binding site, the 
pocket itself has not changed since 1968, although receptor-binding variant 
viruses have been selected in the laboratory (Rogers and Paulson, 1982; 
Temoltzin-Palacois and Thomas, 1994). Sialic acid occupies the entire pocket, 
indicating that it is the dominant component of the influenza virus cellular 
receptor.
The binding site is a depression, the bottom of which is formed by Tyr 
98 and Trp 153. Glu 190 and Leu 194 project down from the short a-helix to 
define the rear of the site with His 183 and Thr 155. Residues 134-138 form 
the right side of the site, and residues 224-228 form the left side (Weis, et al., 
1988) (Fig 5). Comparison of receptor specificities of influenza viruses of the 
H3 subtype has revealed at least three distinct specificities based on preferential 
binding to either one or both of the sialylated oligosaccharides containing SA 
a,2-6Gal or SA 0,2-3 Gal, and showed sensitivity to inhibition by 02 - 
macroglobulin present in the horse serum. Avian and equine H3 isolates, on the 
other hand, preferentially bind SA a , 2-3 Gal and are resistant to horse serum 
inhibition.(Rogers and Paulson, 1983; Rogers, et al., 1983a; Rogers, et al., 
1983b). Virus specificity for these different sialylated receptors was identified 
by selecting variants of H3 strains with different binding specificities.
1.8.8. Antigenic Variation
One of the hallmarks of influenza virus is its ability to undergo 
unpredictable and rapid antigenic variation. Both of the surface glycoproteins 
HA and NA are protective antigens that undergo amino acid substitutions to
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evade immune recognition. Although, antibodies can be, and are, made against 
any structural protein of the influenza virus, it is antibodies that are directed 
against HA that neutralise virus infectivity. These neutralising antibodies focus 
on sites that are clustered around the receptor binding pocket, thus preventing 
att^hm ent of the virus to the host cell sialic acid receptors (Wilson, et al., 
1981).
Antigenic variation alters the nature of the surface proteins such that 
they cannot be recognised by host defence systems but without altering their 
structure enough to affect other essential functions of these proteins: Antigenic 
variation in HA involves two separate processes, antigenic shift and antigenic 
drift.
Antigenic shift occurs only for type A influenza viruses, when a virus 
HA of a novel subtype is newly introduced into the human population resulting 
in new epidemic or pandemic. These are thought to arise by recombination 
between isolates o f different species e.g. avian and porcine (Webster, et al., 
1971) in either one or both of the glycoproteins with up to 80% sequence 
change (Webster, et a l,  1982). Large segments of the population have no 
immunity to these new viruses, because there is little or no serologic relation 
between the haemagglutinin of the new viruses and those of their predecessors. 
Perhaps the best example of an influenza pandemic caused by reassortment 
occurred in 1968, when the H2N2 viruses were displaced by the H3N2 Hong 
Kong subtype. As determined by molecular analysis, the new H3N2 virus 
contained seven of eight genes fi'om the preceding H2N2 strain. Only the H3 
haemagglutinin W2W different (Nakajima, et a l, 1982).
Antigenic drift is less drastic and occurs continually. It results, from 
accumulation of amino acid substitutions primarily in the HAl chain. Changes 
within subtypes are caused by mutations in the RNA genome at sites coding for 
amino acids in exposed areas of either haemagglutinins or of neuraminidases. 
Such changes result in alterations of a subtype’s antigenicity, and they can give
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the new, altered strain a selective growth advantage over the parent strain, 
evading antibody neutralisation during interpandemic years. Gradual 
accumulation of these subtle changes in antigenicity, however, sporadically 
yield epidemic strains.
The molecular location of antigenic variation has been investigated 
using HA-specific monoclonal antibody (mAb) selected variant viruses, and 
single amino acid substitution differences to wild type viruses have identified 
key residues in the 3D structure confirmed by electron microscopy of antibody- 
HA complexes (Wrigley, et a l, 1983). An antibody that recognises any of the 
five antigenic regions is sufficient for virus neutralisation. These mAb-selected 
variants have single amino acid substitutions corresponding to the residues that 
fi'equently change in natural variants, confirming the importance of antibody 
selection in antigenic variation (Underwood, 1982). The fi-equency of selection 
of antigenic variants by monoclonal antibodies is 10"^  -10'^  (Yewdell, et al., 
1979).
1.8.9. Antibody recognition of influenza HA.
There have been some conflicting reports in the literature concerning 
the antibody repertoire for influenza HA. Initial studies on antibody recognition 
of influenza HA were persued by immunisation of BALB/c mice with PR8 
(H lN l) virus, and specificity assigned by haemagglutination inhibition 
reactivity patterns with natural variants. In such studies, extreme diversity in 
the secondary antibody response to influenza . HA was found (Staudt and 
Gerhard, 1983).
Clarke and colleagues also reported highly diverse specificities in the 
secondary antibody response to influenza HA site Sb (equivalent of H3 site B) 
in contrast to the primary antibody responses that were structurally and 
functionally similar (Clarke, et a l, 1985). The secondary antibody repertoire 
reflects the expansion of clones present in the primary repertoire (Cancro, et 
al, 1978), and it has been suggested that the increase in diversity is due to the
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use of both larger repertoire of antibody V-region genes and somatic mutation 
(McKeaa et a i, 1984).
Underwood, studying the secondary response of BALB/c mice 
immunised i.p. with H3N2 virus, showed the highest proportion of antibodies 
were directed against the top of the HA molecule (site B) and the second most 
common site was the trimer interface, suggesting that the antibody repertoire 
of individual mice might be restricted to one or two target areas .
1.8.10. Immunodominance in the antibody response against influenza 
HA.
Previous studies from this laboratory have shown the secondary 
antibody response to be unexpectedly limited following natural infection with 
X31 virus (H3N2). It was shown that there was striking immunodomincmce in 
the neutralising antibody response of CBA/Ca mice (H-2  ^haplotype) (Smith, et 
a i, 1991; Temoltzin-Palacois and Thomas, 1994), BALB/c mice (H-2‘* 
haplotype) and BALB/k congenic mice (Patera, et a l, 1995) following natural 
intranasal infection with influenza virus; a majority of neutralising mAbs, 
established from individual donors focused on a single antigenic site. This was 
deduced by sequencing the HA genes of mAh selected laboratory mutants 
which were found to differ from wild type X31 virus by the same single amino 
acid change, HAl 158 G->E in the H-2*^  haplotype and HAl 198 A->E in the 
H-2** haplotype. Interestingly, in a further analysis of antibody recognition 
specificities for MHC congenic BALB/k mice, there was codominance in the 
selection of laboratory variants, with single residue changes at either HAl 158 
or HAl 198, dependent on the donor origin of the selecting mAb. Sequence 
analysis o f heavy and light chain gene usage indicated that despite 
immunodominance of the two residues, there was extensive progenitor B cell 
diversity contributing to the memory response. Such immunodominance is not 
evident in the neutralising antibody response following inimunisation with 
inactivated virus.
64
In a further analysis of immunodominance, it was demonstrated that the 
introduction of a few mutations in the globular head region of the HAl 
subunit, previously shown to be immunodominant, provided structural 
constraints on further antigenic change in influenza under immune pressure of 
neutralising antibodies (Temoltzin-Palacois and Thomas, 1994). It is interesting 
to note that such constraints resulted in the selection of a receptor-binding 
variant virus (HAl 190 G->D, 226 L->Q); similar amino acid change has also 
been shown in the recent human isolates of the H3 subtype (A/Beijing/92) 
which might indicate similar pressures for immune evasion.
1.8.11. Commonality of B-cell and T-cell recognition site.
The neutralising antibody response to influenza is a thymus-dependent 
event that requires cognate B-cell and T-cell recognition. Initial studies in this 
area indicated that T cells recognise relatively conserved regions of the 
molecule distinct from the antibody binding sites however, immunodominance 
is also observed in the BALB/c and CBA/Ca T-cell response to influenza virus 
HA after natural infection. Despite the potential diversity of the responses, the 
BALB/c (H-2‘*) Th cells recognise predominantly HAl 177-199 (Barnett, et 
a i, 1989) corresponding to site B, or 56-76 (Graham, et a l, 1989), and the 
CBA/Ca (H-2*^ ) Th cells recognise HAl 118-138, or 226-245 or 54-63 (Burt, 
et a l, 1989). HA specific and class H restricted T cell clones elicited by natural 
infection recognise regions of the HAl subunit that have featured in antigenic 
drift. This extensive commonality between antibody and T cell recognition 
specificities may be a consequence of events following natural infection in 
which the memory B cell plays a selective role in the presentation of antigenic 
peptides to T cells. The antigenic properties of HA have been extensively 
analysed using natural variants and mAb-selected mutants to determine the 
location o f antibody binding sites. The CD4+ Th cell recogmtion patterns have 
also been studied and shown to coincide with antibody binding sites (Burt, et 
a l, 1989; Graham, et a l, 1989; Mills, et a l, 1986; Thomas, et a l, 1987), thus
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amino acid changes within these antigenic sites abrogate both T-cell and B-cell 
recognition.
1.8.12. The aim of this investigation.
The main objective of the present studies was to extend the previous 
findings of immunodominance by using two different stratèges: Firstly, 
analysing the memory antibody repertoire using a transgenic murine system in 
which an IgM to IgG class switch, and concomitant affinity maturation, was 
absent and in which the Vh gene usage was restricted. The transgenic mouse 
contained a HuIgH minilocus with human Vh (Vh 26), Dh (Dqs), all of the Jh 
and secretory C|i elements in association an additional Vh (mouse Vh 186.2) 
with targeted disruption of mouse Cp. The question I addressed was how 
diverse or restricted is the memory response? Since IgM antibodies are 
potentially low affmity antibodies compared to moderate affinity IgG 
antibodies, the next question was to whether inability to class switch would 
make any difference to their recognition specificity.
Secondly, an analysis of memory repertoire was made in CBA/Ca mice 
that were infected with X31 virus, underwent hemisplenectomy, and 
rechdlenged with a variant of X31 virus that had amino acid substitutions both 
at known antigenic region and at a Th cell recognition site. The purpose of this 
study was to see a shift, if any, in the memory repertoire. This model system 
was particularly useful because it is possibly closer to the human situation 
where individuals are exposed to recurrent virus infection.
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Materials and Methods
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2. Materials and Methods
2.1. Mice
CBA/Ca mice were bred under specific-pathogen-free conditions at the 
National Institute for Medical Research (NIMR), and were infected intranasally 
with virus at 3-4 months of age.
Human Ig p-chain transgenic mice were kindly provided by Dr. Simon 
Wagner (LMB Cambridge) and were immunised with virus >6 months of age.
CBA/Ca X BALB/c (FI) and nude mice were bred at the NIMR, and were 
used for production, of ascitic fluid.
2.2. Viruses
All influenza viruses were grown in the allantoic cavity of 10-day-old 
embryonated hen eggs at 33®C, the allantoic fluid was harvested after 2 days and 
stored at -70X (Beveridge, 1946 ; Hirst, 1962). Virus titres were determined in 
haemagglutination assays (Salk, 1944). Doubling dilutions of allantoic fluid were 
made in PBS (see appendix I) and 50pl of each dilution was mixed with 50pl of a 
1% TRBC suspenaon. This was incubated at room temperature for 30 minutes. 
The hipest dilution which showed haemagglutination activity was deemed to 
contain IHAU/SOpl thus allowing determination of HA titre of the allantoic fluid.
The X31 virus is a recombinant between A/Aichi/2/68 and A/PR/8/34 
which expresses surface glycoproteins  ^of the H3N2 subtype and PR8 internal 
proteins (Kilboume, 1969).
Natural variants were mainly isolated from the major influenza outbreaks 
between 1968 annd 1984, provided by The World Influenza Centre at NIMR
mAb-selected mutants were produced by growing X31 in the presence of 
neutralising antibody (HI positive) in eggs. Mutants were cloned by limiting 
dilution in ovo and the allantoic fluid was stored at -70°C (further details outlined 
in section 2.11)
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23. Generation of B-cell hybridomas and definition of antibody binding
specificities
2.3.1. Culture media
B cell hybridomas and myelomas were allowed to proliferate in RPMI 
1640 medium (Flow Laboratories), supplemented with Heat inactivated FCS (foetal 
calf serum; Flow Laboratories), 2mM Glutamine (Flow Laboratories), 5x10'^  M P- 
mercaptoethanol (Sigma), 100 U/ml Penicillin, 100 pg/ml Streptomycin (Flow 
Laboratories).
RPMI 1640 (Flow Laboratories) medium was converted to selective HAT 
(hypoxanthine-aminopterin-thyriiidme) medium by addition of hypoxanthine, 
Aminopterin and thymidine solution (all reagents from Flow Laboratories) at a final 
concentration of 100 pM, 0.4 pM, and 16 pM respectively. The HT 
(hypoxanthine-thymidine) medium was prepared in the same way, but without 
aminopterin.
2.4. Production of mAbs.
CBA/Ca mice were infected intranasally and /or immunised with 5 HAU of 
X31, allowed to recover for six to ten weeks. Following intraperitoneal boost with 
2000 HAU three days prior to hybridoma fusion, half spleens were removed 
surgically under general anaesthesia (kindly performed by Ms V. Attenburrow) and 
used to generate B cell hybridomas. Splenic lymphocytes from individual donors 
were fused with the BALB/C derived myeloma line JK-AgS (P3-X63-Ag8653) 
(Kearney, et cd., 1979; Kohler and Milstein, 1975) following the Fazekas de St. 
Groth and Scheidegger (1980) protocol. After 8-10 weeks, mice were infected 
with 2000 HAU of a variant virus A43 (HAl 158, HAl 145 and del HAl 224- 
230), boosted intraperitoneally with 5000 HAU and the other half spleens used to 
generate B cell hybridomas.
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Human Ig p-chain transgenic mice were immunised intraperitoneally with 
inactivated X31 and whole spleen was used to generate B-cell l^ridomas.
Equal number of washed spleen cells and myeloma cells were fiised in 1ml 
of a 50% solution of PEG (polyethylene glycol mol. wt. 1,300-1,500; Sigma) in 
RPMI 1640 and 50 pi of DMSO (dimethyl sulphoxide; BDH). After gentle 
Rhflking for 5 min. at 37° C, the cells were washed and resuspended in medium 
with 20% FCS and HAT. 50 pi aliquots of fused cdls were added to 150 pi of 
PECs (peritoneal exudated cells) in selective medium, in flat-bottom-96-well- 
microtitre plates, and cultured at 37°C in 6% COz: 2x10^ spleen cells and PECs 
from one mouse, were dispensed onto each plate. On day 5,100 pi of medium was 
removed fiom the cultures and replaced with lOOpl of HAT medium containing 
20% FCS. On day 14 , this procedure was repeated but this time 100 pi HT 
medium was added. Subsequently, fresh standard culture medium containing 10% 
FCS was added when required.
Hybridomas were screened for anti-HA activity by haemagglutination 
inhibition assays* andmAb isotypes determined by ELISA (Ishiguro, et aL, 1983). 
mAbs bound to X31 were detected using biotinylated goat anti-mouse Ig isotype 
specific antibodies (Southern Biotech) and Streptavidin-alkaline phosphatase 
conjugate (Southern Biotedi) developed with p-nhrophenyl phosphate at 1 mg/ml 
in diethanolamine buffer (see appendix I) and the absorbance at 405 nm was 
measured. For transgenic mice, anti-K or anti-X light chain antibodies (Sigma) were 
used.
23.Haemagglutmation Inhibition (HI) Assay.
Culture supernatants were screened for HA-spedfic neutralising antibody 
in a haemagglutinm inhibition (HI) assay (WHO e?q>ert committee on influenza,
1953) from day 10. Two-fold serial dilutions in PBS of 50pl antibody samples 
were made in round bottom 96 well mlŒOtitre plates. Eight HAU of virus in 25pl
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volumes was added to eadi well and the plates incubated at room ten:4>erature for 
30 minutes. 25 pi of a 2% turkey RBC suspension was added to each well and 
incubated for a further 30 min at room temperature to allow agghitinatioa Positive 
hybrids were allowed to attain confluency and then transferred to a 24 well plate 
(Costar) containing PECs and 2 ml of standard medium supplemented with 10% 
FCS per well.
2.6. Cloning and expansion of HA specific hybridomas.
Once confluent in the Costar plates, HA specific hybridomas were doned 
by limiting dilution. Briefly, flat bottom 96 well microtitre plates were seeded with 
lOOpl of a PECs suspension in RPNfl 1640 medium containing 20% FCS. The 
hybridoma cells were diluted to a final concentration of 3 cell/ml (équivalut to 0.3 
cell /well) and then lOOpl/well were added to the 96 well plates. After 10-14 days 
the wells were screened for HA spedfic antibodies in HI assays. The positive 
clones were expanded in 24 well plates and wdien confluent, transferred to 25 cm  ^
flasks (Falcon). Large amounts of HA specific mAbs w ae generated by growing 
l^bridomas as asdtic tumours in mice. Briefly, (CBA/Ca x BALB/c) FI mice were 
given a sih^e 0.5 ml intraperitoneal ngecdon of Pristane (2,6,10,14 tetramethyl 
pentadecane; Koch light) one week before the intrtqperitoneal iigection of at least 
1x10® hybridoma cells per mouse in 1.5 ml of PBS. Each mAb was used to sdect 
a neutralising escape mutant.
2.7. mAb isotype determination.
The mAb isotype determination was performed uâng standard indirect 
ELISA techniques (Ishiguro, et cd., 1983). Briefly, plastic 96 well microELISA 
plates (Nunc) were coated with Ipg/well BHA or 100 HAU of whole virus in 
borate buffered saline saline pH 8.6 (BBS, see appendix I) for 2 hours at 37°C and 
washed three times with PBS-Tween 20 (0.05%; Sigma) allowing a 1 min soak
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between washes. 50pl hybridoma culture medium supernatant or asdtic fluid was 
added to each well, and a negative control of PBS-Tween set up. The plates were 
incubated at room tenq)erature for 1 hour and then washed again (3x). mAbs 
bound to BHA were detected by adding SOpJAvell 1:1000 dilution in PBS-Tween 
of biotinylated goat anti-mouse Ig isotype specific antibodies (Southern Biotech) 
for 2 hours at room temperature. The plates were washed as before and then 
SOplAveU of strq3tavidin-alkaline phosphatase corrugate (1:1000 dilution in PBS- 
Tween) (Southern Biotech) was added for 1 hour at room temperature. Plates 
were then developed with SOplAvell p-nitrophenyl phosphate (Sigma) in IM 
diethanolamine buffer pH 9.8 (Sigma), the reaction stopped by addition of 50pl of 
5 M NaOH (BDH) and the absorbance at 405iun was measured.
IgM mAbs were detected with alkaline phoq>hatase-coiyugated goat 
antibodies specific for mouse k  or A. light chain (Sera-lab) used at a dilution of 
1:1000 in PBS-Tween.
23. Virus spedfidty for neo-glycoprotdns.
Substrates a , 2-3 sialyUactosarninyl-BSA (Dextra Laboratories) and a , 2-6 
sialyllactosaminyl-BSA (Prepared in the laboratory by enzymatic modification of 
N-acetyllactosaminyl-BSA using a , 2-6 specific neuraminyl transferase and CMP- 
N-acetyllactosaminidate, (as recomended by the manufecturer Boehringer, 
Mannheim Biochemica) were coated on ELISA plates at 30 pg/ml respectively. 
The plates were incubated overnight at 4°C, washed x4 and blocked with 2.5% 
BSA The plates were washed as before and X31 and variant viruses were added at 
50 and 100 HAU/lOOpl, and incubated for one hour at room tenq)erature. The 
plates were washed and blocked again with BSA followed by addition of 50|j1 of 
rabbit anti-HA Ab at 1:3,200 dilution Çm PBS-Tween) and incubated for an hour at 
room tenq)erature. Plates were washed again as before and 50pl of Goat anti­
rabbit IgG-alkaline phosphatase cogugate (Sigma) was added at 1:1000 dilution
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for an hour at room temperature. Plates were then devdoped with SOpl/well p- 
nitrophenyl phosphate (Sigma) in IM diethanolamine buffer pH 9.8 (Sigma), the 
reaction stopped with 5 M NaOH (BDH) and the absorbance at 405nm was 
measured.
2.9. Neuraminidase treatment of IgM mAbs.
Neuraminidase purified fi'om Vibrio cholerae (Boehringer Mannheim) used 
at 1 unit/ml was mixed with IgM mAb containing ascitic fluid and incubated 
overnight at 37°C followed by a 2 hour incubation at 56°C to inactivate 
neuraminidase.
2.10. Neutralisation assay.
MDCK cells were grown in DMEM (Dulbecco Modified Eagle’s medium: 
Gibco BRL) supplemented with heat inactivated FCS (foetal calf serum; Flow 
Laboratories), 100 U/ml Penicillin, 100 pg/ml Streptomycin (Flow Laboratories) in 
small petri plates (Nunc).
Virus-mAb was mixed and left for one hour at room temperature. 
Confluent MDCK cells were washed with DMEM, the virus-mAb mix was added 
and incubated for 30 minutes at 37°C. DMEM at 4°C (supplemented with 
glutamine, trypsin: 0.25%, non-essential amino add and antibiotics) was mixed 
with hot agar (70° C) and added to the plate and incubated at 37°C for a further 48 
hours. Plates w ^e assayed for plaque forming units (PFU) following fixation with 
0.25% (v/v) ghitaraldehyde for 20-30 minutes after whidi plates were stained with 
1% (w/v) crystal violet for 10 minutes. Colonies were counted manually following 
destaining.
2.11. Selection of mAh neutralisation escape mutant viruses.
73
Monoclonal antibody selected mutants were produced by growing X31 in 
the presence of neutralising antibody in %gs. Allantoic fluid, containing 2000 
HAU/ lOOpl of X31, was mixed with an equal volume of neat ascitic fluid and 
incubated at room temperature for 30 minutes. SOOpl aliquots were iiyected into 
ten-day-old-embryonated hen eggs. Allantoic fluid was harvested on day three and 
tested for mutant virus by haemagghitination inhibition (HI) assay (World Health 
Organisation Expert Committee on influenza, 153). Escape mutants were cloned 
by limiting dilution.
2.12. Purification of viruses.
X31 and mAh selected variants were purifled fl*om allantoic fluid 
using the method described by Skehel and Schild, 1971. Briefly, the allantoic fluid 
was clarified by spinning at x 500 g for 20 min at 4°C (using a Beckman JS-4.2 
swinging buricet rotor). The virus was then pelleted by spinning at x 23,000 g for 
two hours at 4°Ç (using a Beckman T19 fixed angle rotor). The pellet obtained 
was resuspended in 3-4 mis Tris/saline (see appendix I), homogenised or sonicated 
for 5 minutes in a water bath sonicator (Camlab Transonic T310). The resulting 
suspension was then loaded onto a continuous gradient of 15% - 40% sucrose w/v 
in Tris/saline and uhracentrifliged at x80,000g for 45 min at 4°C (using a Beckman 
SW28 swinging bucket rotor). The virus band, clearly visible about half way down 
the gradient was harvested, diluted to 30 ml in Tiis/saline. The virus was pelleted 
by spinning at x 80,000g for 90 minutes 4°C (SW28 rotor) and resuspended in 0.5 
ml Tris/saline. (Skehel and Schild, 1971).
2.13. Bromelain digestion of influenza virus to produce BHA.
X31 and variant virus haemaggtutinins were cleaved by digestion with 
bromelain. lOmg of purified virus was mixed with 5mg of bromelain (Sigma) in 
3mls of digestion buffer (Tris/saline with 50mM p-mercaptoethanol, 0.1% sodium
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azide) and incubated at 37°C for 2 hours. The reaction mix was then spun at 
xllO,OOOg for 30 minutes at 4°C (in a Beckman SW41 swinging-bucket rotor). 
The pellet was resuspended in 3mls of digestion buffer containing 5mg of 
bromelain and incubated at 37®C for 3 hours. The reaction mix was spun as before. 
The supernatant was collected and the pellet was resuspended in 3mls of digestion 
buffer containing 5mg bromdain and incubated at 37°C overnight. The reaction 
mix was spun as before and the supernatant collected. The supernatant was layered 
onto continuous gradients of 5-25% sucrose w/v (1.5ml of supernatant/ gradient) 
and sçsm at xl50,000g for 15 hours at 4°C (SW41 rotor). The gradients were 
harvested by collecting 1ml factions fom  the bottom of the tube using a peristaltic 
pump. The absorbance at 280nm was measured and those factions which 
contained protein were pooled.
The BHA solution, generally in a volume of around 12mls, was 
concentrated down to a volume of 3 mis using an Amicon Ultrafiltration Stirred 
Cell System with a 10,000 mol.wt filter cut off Protein concentration was 
determined by measuring the absorbance at 280nm and the purity of preparation 
was checked by gel electrophoresis (see section 2.14).
2.14. Cd Electrophoresis of Proteins.
The purity of BHA preparation was assessed by SDS-polyacrylamide gel 
electrophoresis. Samples were electrophoresed through a stacking gel containing 
4% acrylamide, 0.25% Bisaoylamide, 0.1% SDS (all fom  BDH) in 60mM Tri&- 
HCl pH 6.7 and a separating gel containing 12.5% acrylamide, 0.25% 
Bisacrylamide, 0.1% SDS in 0.4 M Tris-HCl pH 8.9. The electrophoresis buffer 
was Tris/Glydne buffer pH 8.3 (see ^ pendix I).
10 pi of sample was mixed with 10 pi of either a redudng or non-redudng 
loading buffer (see appendix I), boiled for two minutes and loaded onto the gel. 
200 volts was applied across the gel for 50 minutes. Gels were stained in 40% 
methanol, 10% acetic add, 0.5% coomassie blue for 10-30 minutes and then de­
stained in 40% methanol, 10% acetic add.
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2.15. Horse Serum Inhibition Assay.
Two-fold serial dilutions in PBS of horse serum were made in round 
bottom 96- well microtitre plates. Eight HAU of X31 or variant virus in SOpl 
volumes was added to each well and the plates incubated at room tenq>erature for 
1 hour. 50 pi of a 1% TRBC suspension was added to each well and incubated for 
a further 30 min at room temperature to allow agglutination.
2.16. RNA extraction from purified virus.
Viral RNA was extracted according to Hay et al., 1977. 2-10 mg/ml 
purified virus was solubilised in 60 mM sodium acetate pH 5.0 (BDH), 6 mM 
ethylene diamine tetracetic add pH 7.0 (EDTA BDH) and 1% sodium dodecyl 
sulphate (SDS: Sigma). The RNA was extracted 2-3 times with an equal volume of 
phenol/chloroform/isoamjd alcohol (25:24:1). RNA was predpitated from the 
aqueous phase with 20 mM NaCl (BDH) and twice the volume of absolute ethanol 
on dry ice for 1-2 hours. The pellet was collected by centrifuging at 13,000g for 10 
minutes at 4°C, dried, redissolved in sterile doifole distilled water and the 
concentration was calculated from the A 26o value and the A 26o • A 2so ratio was 
determined. RNA sangles were stored at -20X.
2.17. Viral RNA extraction from allantoic fluid.
200 ml of the allantoic fluid was mixed with 200 pi TES buflèr (see 
appendix I). RNA was extracted 2-3 times with an equal volume of 
phenol/chloroform, aqueous phase recovered and the RNA predpitated with 
1/10th of the volume of 2 M NaCl and double the volume of chilled absolute 
ethanol on dry ice for 1-2 hours. The pdlet was collected by cmtrifoging at 13000
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g for 10 min, 4°C, dried, dissolved in sterile double distilled water and used for RT- 
PCR amplification.
2.18. cDNA synthesis from viral RNA.
cDNA was synthesised fix>m viral RNA in a 20 pi volume of buffer 
containing 100 mM Tris-HCl pH 8.3,10 mM MgClz, 800 mM 200 mM KCl, with 
40U of AMV Reverse Transcriptase (Boehringer Mannhdm), 25U RNAsin 
(Amersham), 0.67 mM FHA (see 2.21) and 40mM dNTP. This was incubated at 
42°C for 1 hr. Samples were then boiled at 100°C for 3 minutes, then qumched 
immediately on dry ice.
Samples wa*e then thawed and spun for 10 min in a microfiige. The 
cDNA containing supernatant was used in PGR. Each reaction was set up in 100 pi 
volume containing 10 mM Tris pH 8.8, 1.5 mM 50 mM KCl, 2.5%
glycerol v/v, primers FHA and RHA2 (see 2.21) at 0.5 pM, each dNTP at a 
concentration of 250 pM, 2.5 U Taq polymerase (Pharmacia Biotechnology) and 
20 pi of cDNA template. Each tube was then overlaid with a drop of mineral oil 
(Sigma). Once amplified, PCR products were visualised by running a 5 pi sample 
together with 1 pi sucrose gel dye (45% sucrose, 0.25% bromophenol blue) on a 
1% agarose gel in 1 x TBE (100 mM Tris-base, 100 mM boric add, 5 mM EDTA 
pH 8, 0.5 mg/ml ethidium bromide) at lOOV. The amplification cycle was 1 x 
(95°/3 min, 50V1 min,70° /1.5 min), 40 x (95° /I min, 50°/ Imin, 70° /1.5 min), Ix 
(70°/5min).
2.19. Purification of PCR products for sequencing.
A 40 pi sample of the anq)lified product mixed with 5 pi sucrose dye was 
loaded equally into two adjacent wells of a 1% low melting point agarose (PMC 
Sea Plaque: Sigma) gel in TBE (see appendix I) with ethidium bromide. Molecular
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weight marker was also loaded onto the gel which was run at lOOV. The gel was 
then viewed on a low intensity UV light box and bands of correct size cut and 
placed in eppendorf tubes. DNA was recovered from gel slices by melting the 
agarose at 75°C for 30 minutes fi)llowed by purification uang Wizard PCR Prep 
(Promega) following the manu&cturer's instructions. A 2 pi sangle of the purified 
DNA was run on a 1% agarose gel in TBE together with a known concentration of 
DNA molecular weight mark^ to estimate the concentration of DNA in the sample 
for sequencing.
2.20. Direct sequencing of PCR products.
the PCR product was determined using a modified chain terminating method 
(Sanger, et aL, 1977). Purified PCR product was mixed with primer to a template; 
primer molar ratio of between 1:35 and 1:70 in 3 pi. This was added to 3 pi of 
annealing mix (125 mM Tris-HCL pH 7.5, 50mM MgClz, lOOmM NaCl, 20% 
DMSO). Different primers used were FHA, DP, CCP2, CCP4, RHAl and RHA2 
(see 2.21).
Samples were incubated at 100°C for 3 minutes, immediately quenched on 
dry ice, thawed afi^ 5 min, briefly centrifiiged and then 4 pi of labelling mix (25 
mM DTT, 2.6 u sequenase and 10 pCi ^^S-dATP) was added to each reaction 
tube. 2.5 pi of template/ primer mix was added to 2pl of each of the 4 dNTP/ 
ddNTP mixes. These nuxes contained dGTP/ CTP/ TIP at 80pM and one ddNTP 
at either 8pM (ddG/C/T) or 0.16pM (ddATP) in 20% DMSO. This was incubated 
at 37°C for 5 min, followed by 2 pi of (base mbc (0.25 pM of each dNTP, 50 mM 
NaCl, 10% DMSO) and then incubated again for further five minutes before the 
reaction was stopped by addition of 6 pi per well of formamide dye. This reaction 
mix was boiled for 3 minutes and run immediately on denaturing 8% 
polyacrylamide gel containing 8 M Urea in TBE Gels were dried for 1% hours at 
85°C under vacuum on a gel drier (Biorad model 583) before autoradiography
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(Kodak film) for 24-72 hours at room temperature. Autoradiogr^hs were read 
and sequences recorded .
2.21. Primers used in amplification and sequencing of the HAl gene of
influenza virus.
FHA TGAAGACCATCATTGCTTTGAGC
DP TGCTACTGAGCT
CCP2 GAGACATGGGACCTTTTCTT
CCP3 TCACTTGGACTGGGGTCACT
CCP4 CAGTAGACTGAACTGGTTGA
m iA i TCGAAGGTAAAGCTGACTACGT
RHA2 AGATAGTAAGGGAGGGITGGTAA
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3.1. Introduction
The recognition sites for neutralising antibodies have been previously 
located to five regions (A->E) on the membrane distal ectodomain of the HAl 
subunit (Caton, et a l, 1982; Gerhard, et a l, 1981; Lubeck and Gerhard, 1981; 
Underwood, 1982; Wiley, et a l, 1981). All of these exposed regions, proximal 
to the receptor-binding pocket are potential recognition sites for neutralising 
Abs. However, recent studies from this laboratory have shown the secondary 
antibody response to be unexpectedly restricted in specificity following natural 
infection with X31. It has been shown that there is striking immunodominance 
in the neutralising antibody response in different strains of mice. As deduced by 
sequencing the HA genes, mAh selected laboratory mutants were found to 
differ from wild type X31 virus by a single amino acid change, HAl 158 G->E 
in the H-2^ haplotype, (Smith, et a l, 1991; Temoltzin-Palacois and Thomas, 
1994) HAl 198 A-^E in the H-2‘* haplotype and there was co-dominance in 
MHO congenic BALB/k mice with a single residue change at either HAl 158 
or HAl 198, depending on the donor origin of the selecting mAh (Patera, et 
a l, 1995). This contrasts with the diversity of antibody specificities seen 
following i.p. immunisation of BALB/c mice with inactivated virus (e.g. HAl 
63, 135, 143, 144, 145, 156, 189, 198, 199, 205).
There is considerable knowledge of antibody responses in CBA/ Ca, 
BALB/c and BALB/ k mice to virus infection as well as heavy and light chain 
gene usage. Patera et al. (1995) have shown recently that, despite 
immunodominance of the above two residues, there was extensive progenitor 
B cell diversity contributing to the memory response; the individual’s response 
to a single antigenic site was derived from a minimum of 3-6 progenitor cells. I 
wished to extend these findings to an analysis of the memory repertoire of 
transgenic mice expressing human p chains in the absence of endogenous 
murine p chains, following immunisation with X31 virus. These mice were 
made by crossing transgenic mice carrying a human Ig H chain gene with mice 
that had been rendered deficient in endogenous immunoglobulin production by
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gene targeting (Wagner, et a/.,1994). The DNA construct used for integration 
is shown in figure 6 (Bruggemann, et a l, 1991).
This transgenic model provides a unique opportunity to investigate the 
neutralising antibody response under conditions in which (a) there is no class 
switching fi’om IgM to IgG, and affinity maturation due to somatic 
hypermutation and (b) highly restricted Vh region gene usage.
I wished to determine whether a low affinity IgM antibody response 
would be similarly focused on a limited region(s) of the HAl subunit.
82
Fig 6: Structure ofhumanig H cosmid.
Cos 25 contains the subcloned Vh 26, D segments ( D21/ 10, D3, 
D21/ 9, DQ 52), the functional J segments, the intron enhancer (E) 
the p constant region of the human IgH gene, and an additional 
mouse Vh 186 gene with disruption of mouse membrane p.
(C p ) and the membrane p ( M p ).
HuIgH
Hue  MoE 
Vh26 Vh*®® Ds DQ52J1-6 \ I
1 kb
3.2. RESULTS
3.2.1. Generation of HA specific B-celi hybridomas from Hulg-p chain 
transgenic mice.
In an investigation of the neutralising antibody response to HA in 
transgenic mice (Tg) expressing human Ig heavy chains, the following 
strategy was employed (Fig 7): Tg mice were immunised intraperitoneally 
with 1000 units of UV inactivated X31 virus and boosted 3 days before 
spleens were taken for B-cell hybridoma production. B-cell hybridomas 
secreting HA-specific neutralising antibodies, were screened for by 
inhibition of viral haemagglutination (HI) of turk^ erythrocytes.
Thirty out of sixty hybridomas (the TgM series) were cloned by 
limiting dilution. These antibodies were eloned in 96 well microtitre plates 
at about 0.3 cell/ well and considered clonal if ten to twelve wells/plate 
were HI positive. A total of four HA-specific hybridomas were obtained 
from one donor and high titer mAb-bearing ascitic fluid was obtained by 
further expansion in r|u/ T|u mice (table 1). Equivalent HI titers were 
obtained for each of the selected mAb.
3.2.2. mAh recognition specificity for variant viruses.
In an initial attempt to determine their fine specificity, mAbs were 
tested by HI assay against a panel of laboratory variant viruses with known 
single amino acid substitutions within the HAl subumt (table 2). The 
results, however, did not provide a definitive assignment of amino acid 
residues in the HAl subunit that constituted part of the antibody 
recognition site. For instance mAbs 7.1 and 21.2 recognised all variants in 
the HI assays with the singular exception of the mutant M l-9 (HAl 226 
L-K), 135 G ^V ). However, the variants containing the corresponding 
single substitutions HAl 226 L->Q or HAl 135 G->R/ D were recognised. 
Hence, the structural basis for recognition specificity could not be
Fig 7: Schematic representation to show generation of mAbs
X31
infection
boost
Splénocytes + myeloma cells
protective mAbs
A scites + X31
neutralising esca p e  
mutants
HA gen e  sequencing
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Table 1: HI reactivity of anti-HA mAb containing ascitic fluid against
X31.
HI titre expressed as the reciprocal of the dilutions required
to inhibit agglutination of turkey erythrocytes by 100%.
mAb ( ascites ) -HI titers (X31)
1.1 51200
4.1 12800
7.1 25600
21.2 51200
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Table 2: Values indicate HI titres for mAb-containing ascitic fluid, in
the agglutination of turkey erythrocytes by X31 or its laboratory variants.
HI titre expressed as the reciprocal of the dilutions required to
inhibit agglutination o f turkey erythrocytes by 100%.
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Table 3 : Haemagglutinin inhibition specificity of TgM-mAbs for
natural isolates of the HI, H2 or H3 subtype.
HI titre expressed as the reciprocal o f the dilutions required to
inhibit agglutination o f turkey erythrocytes by 100%.
NR; not recognised.
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Table 4; Haemagglutinin inhibition specificity of TgM-mAbs for 
natural isolates of the HI subtype.
HI titre expressed as the reciprocal of the dilutions required to
inhibit agglutination of turkey erythrocytes by 100%.
< HI titre below 100.
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Table 5: Haemagglutinin inhibition specificity of TgM-mAbs for
natural isolates of the H2 subtype.
HI titre expressed as the reciprocal o f the dilutions required to
inhibit agglutination o f turk^ erythroeytes by 100%;
< HI titre below 100.
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established. In contrast, the remaining mAbs 1.1 and 4.1 fixiled to recognise 
HAl 135 G->R. There was some considerable degree of variation in HI 
reactivity for the panel of variant viruses as illustrated by heteroclitic 
reactivity of mAb 7.1 for 158 or reduced reactivity for 135 or 145. The 
reactivity of mAbs 1.1 or 4.1 was sensitive to HAl 135 G->R change.
Since each of these mAbs was cross-reactive in the above HI assay, 
there was some concern as to whether mAbs were indeed specific for X31. 
The serological assays against a panel of HI, H2 and H3 subtype viruses 
(table 3, 4, 5) do indicate fine specificity since none of the mAbs 
recognised either HI, or H2 subtype viruses.
3.2.3. Selection and sequence analysis of X31 laboratory variants.
To obtain a definitive assignment of neutralising antibody binding 
sites, the above mAbs were used to select laboratory mutants of X31. The 
HA gene of each cloned laboratory mutant was sequenced and the amino 
acid substitution was deduced fi*om the nucleotide sequence data. Four 
mutants were selected and characterised using TgM antibodies and named 
the TgMm series (table 6). Three out of four mutants had amino acid 
S u b s t i t u t i o n s  a t  t w o  different positions on the HAl subunit. A common 
change, residue HAl 135 G—>R was present in majority of the mutants and 
the other changes were either proximal to, or within the receptor binding 
site as shown in table 6.
3.2.4. Novel feature of TgM mutants.
One of the interesting features of the TgM mutants was the 
occurrence of double mutations: one of the amino acid substitutions was 
present in a conserved residue that constitutes part of receptor binding 
pocket, and the other amino acid substitution in a region of known 
antigenic change: Mutant 7.1, selected by mAb T ^ -7 .1 , had substitutions
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Table 6: Recognition specificities of mAb as deduced by sequencing
of the HA genes of mAb- selected X31 mutants.
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at positions HAl 226 L->P, and 145 S->N. HAl 226 has been shown to be 
crucial in host-range restriction and thus change at this position alters the 
receptor binding characteristics of the virus. The other two antibodies 1.1 and 
21.2 also selected double mutants. Antibody 21.2 selected a variant with a 
substitution at HAl 225 and a further amino acid change at HAl 135 
G->R. HAl 225 is also a conserved residue located within the receptor- 
binding pocket. Antibody 1.1 selected a variant with changes at HAl 135 
G->R and HAl 158 G->E. Residue 158 has been implicated in receptor 
binding specificity and both HAl 145, and HAl 158 occupy positions in close 
proximity to the receptor binding site (Underwood, et a l, 1987).
3.2.5. HI reactivity of TgM mAbs for their own mutants.
Table 7 shows the reactivity of the TgM mAbs with mutants that they 
had selected as well as relevant single mutants. mAb 7.1 and 21.2 do not 
recognise their “own” mutants HAl 145 S-»N, 226 L-»P and HAl 135 G—>R, 
225 G—>D respectively. However, variants with single residue changes at these 
positions, 135 G—>R or 226 L—>Q or 145 S ^ N  or 158 G—>E were all 
recognised. Similarly, mAb 1.1 and 4.1 failed to recognise their selected 
variants HAl 135 G->R, 158 G ^E  and HAl 135 G->R respectively but were 
found to be sensitive to changes in m-21.2. The HAl 226 L->Q variant virus 
was used in all above assays since laboratory variants with single residue 
change at 226 L->P or 225 G-^D have not been reported. It was not possible 
to establish whether failure to recognise the selected virus required either (a) 
amino acid changes at both positions or (b) the same critical residue change at 
HAl 226 L->P or HAl 225 G-^D. Also different amino acid substitutions at 
the same position are known to affect antibody recognition and specificity.
3.2.6. mAb reactivity for variant viruses in ELISA.
Since all the mutations had occurred either proximal to or within the 
receptor binding pocket, and might affect receptor binding, it was necessary to
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Table 7: HI reactivity of TgM antibodies
with TgM mutants compared to X31.
<:  <100
HI titre expressed as the reciprocal of the dilutions required to 
inhibit agglutination of turkey erythrocytes by 100%.
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Pig 8: mAb recognition specificity for variant viruses by ELISA.
(a) Reactivity of mAb 21.2 ( • ) ;  or mAb 7.1 (A) or mAb 4.1 (■) with 
variant virus m-21.2.
(b) Reactivity of mAb 1.1 with variant virus m-l.l(#% or mr7.1 (A ) or 
m-4'jl(H)>-
Procedures as described inMethods section 2 7  for ELIS A. .
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Fig 9: mAb 7.1 recognition of variant viruses by ELISA.
(□) 145 S^N; (A) X31; (0) 226 L^Q; (#)m-7.1 (HAl 145 S->N, 226 
L-^P).
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Fig 10: mAb 21.2 recognition of variant viruses by ELISA.
( • )  X31; (□) m-7.1 (HAl 145 S^N , 226 L->P); (A) m-1.1 (HAl 135 
G-^R, 158G-^E);
(A)m-4.1 (HAl 135 G-^R);
(■) X31-HS (HAl 226 L->Q).
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establish whether the laboratory variant viruses containing these substitutions 
were antigenic or receptor binding-variants. Each mAh was tested by ELISA 
assay for its ability to bind to the mutant virus which it had selected. Antibody
7.1, that had selected a variant HAl 145 226, recognised and bound to variant 
viruses with single amino acid substitution either at position 145 S—>N or HAl 
226 L—>Q but failed to recognise its selected variant. A heteroclitic response 
was seen to variant 145 S—>N as compared to X31 (Fig 9).
Antibody 1.1, that had selected HAl 135 G-^R, 158 G->E also failed 
to bind to its selected mutant. This effect might be due to the substitution at 
position 135 G->R which is not recognised by the antibody either in ELISA as 
shown in fig 8b or in HI (table 7). These viruses therefore qualify as antigenic 
variants.
3.2.7. mAb 21.2 still binds to its variant (HAl 135, 225) in ELISA.
mAb 21.2, that had selected a variant with changes at positions HAl 
135 G->R and HAl 225 G->D, still recognised its selected mutant in ELISA 
And although antibody binding was reduced (as compared to X31; fig 10), it 
qualifies as a receptor-binding rather than antigenic variant. mAb 21.2 also 
bound well to HAl 135 G->R or HAl 226 L—>Q.
It should be emphasised that neutralising antibodies do not usually 
recognise conserved regions of HAl resulting in the selection of variant viruses 
with changes in the receptor-binding pocket.
3.2.8. Is terminal Sialic acid, a selective determinant ?
IgM antibodies are glycoproteins containing terminal sialic acid and all 
the mutants selected had substitutions either in the receptor binding pocket, or 
of residues proximal to the pocket. The question therefore arose as to whether 
terminal sialic acid (SA), present on the mAbs, was playing a role in the 
selection process. For this reason, mAb-containing ascitic fluid were incubated
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Fig 11: PNA ( peanut agglutinin) binding to NANAse treated IgM
mAb (0) or untreated mAb.(D) in ELISA
Wells coated with mAbs (used at 400 ng/ ml) were incubated with 
biotin-conjugated PNA, followed after washing by alkaline phosphatase 
conjugated Streptavidin, followed by substrate addition, as described in 
Methods, section 2.7.
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overnight with neuraminidase to remove SA. To monitor the removal of 
SA, binding assays were performed with two different lectins, as shown 
(fig 11). Peanut agglutinin (PNA) binds to terminal galactose residues of 
glycoproteins whereas Elderberry bark lectin has specificity for terminal 
SA. Following enzymatic digestion, the binding of Elderberry bark lectin to 
neuraminidase (NANA) treated antibodies was reduced to base line, with a 
reciprocal increase in binding of PNA, thereby confirming the efficacy of 
NANAse treatment.
3.2.9. Selection of mutants with NANAse treated mAbs.
mAbs, 7.1, 21.2 and 1.1 that had previously selected HAl 145 
S->N, 226 L->P; HAl 135 G->R, 225 G->D, and HAl 135 G-^R , 158 
G—>E respectively were used to select mutants of X31 after treatment with 
NANAse. Several rounds of selection were done with different dilutions of 
both mAb and virus before mutants were obtained: table 8 shows the 
mutants that I have characterised: mAb 21.2 was again found to select 
HAl 135 and 225, mAb 7.1 selected variant 135/ 225 or 145/ 226 in two 
different selections.
It is therefore reasonable to conclude that SA was not responsible 
for the selection and this is consistent with the failure of the mAbs to bind 
viruses of different subtypes.
3.2.10. Neutralisation assays with NANAse-treated and untreated 
TgM antibodies.
HI is usually considered a reliable index of virus neutralisation: 
antibody inhibits haemagglutination by blocking t h e  r e c e p t o r  binding site. I 
wished to confirm that the antibodies not only prevented attachment of 
virus host cell receptors but also neutralised virus infectivity. Briefly, X31, 
or the TgM mutants or other natural virus isolates were incubated with 
different dilutions of mAbs for an hour, layered on trypsinised MDCK cells
100
and incubated for three days at 37° C. All mAbs failed to neutralise their 
own mutants as well as the natural isolates as was seen by the appearance 
OÎplaques. X31, however, was recognised by both treated and untreated 
mAbs and hence no colonies were observed.
101
Table 8 : Recognition specificities of NANAse treated mAbs as
deduced by sequencing the HA genes of mAb selected X31 mutants.
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3.2.11. Summary
A panel of neutralising IgM mAbs was established from transgenic 
mice, expressing a human Ig H minigene, following immunisation with X31 
virus. Their recognition specificities for HA were determined by the selection 
and sequencing of X31 laboratory variants. The majority of variant viruses 
differed from wild type by two amino acid residue changes, including 
substitutions in conserved residues that constitute part of the receptor binding 
pocket.
First, consider the receptor specificity of mAb 7.1 that initially selected 
a laboratory variant (HAl 145 S—>N, 226 L—>P). These residue changes 
represent small polar (S) to small polar (N), or large non-polar (L) to small 
non-polar (P) changes within the HAl subunit. HAl 145 is a known antigenic 
site that has featured in the residue changes of both natural variant viruses 
(S^N ; VIC/75 or TEX/ 77) and laboratory variants (S^N , S->R, S->K). 
HAl 226, however, has been a conserved residue for all of H3 natural isolates 
obtained between 1969 and 1990 and has not been selected for, hitherto, by 
neutralising mAbs. It is part of the receptor binding pocket and variant viruses 
at this position can be selected for by glycoprotein inhibitors. Following 
NANAse treatment of mAb 7.1, a further laboratory variant (7. IN) was 
selected containing residue changes 135 G—>R (small polar to large polar) and 
225 G->D (small polar to small polar). Here again HAl 135 has been 
demonstrated to be an antigenic site and laboratory variants of X31, containing 
this single residue change, have been selected for by neutralising mAbs of the 
IgG class. However, HAl 225 is a highly conserved residue in H3 subtype 
viruses and, once again constitutes part of the receptor binding pocket.
It should be emphasised here that a majority of previously reported 
laboratory variants differ from the wild type by a single residue change within 
one of the five major antigenic sites.
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CHAPTER-4
Receptor-binding characteristics of mAb-selected variants
104
4.1. Introduction
Haemagglutinin is responsible for the attachment of the virus to cell 
surface glycoconjugates by binding to terminal sialic acid (SA) residues (Wiley 
and Skehel, 1987). Binding to SA involves a shallow pocket of conserved 
amino acid residues near the membrane-distal tip of each subunit as defined by 
crystallographic studies of oligosaccharide-HA complexes (Weis, et a l, 1988). 
Sequence analyses of the receptor variants e.g. X31-HS, selected with non- 
immune horse serum, indicated that differences in receptor specificity could be 
accounted for by a single amino acid residue change HAl 226 L->Q, which is 
located in the receptor-binding pocket (Rogers, et a l, 1983a; Rogers, et a l, 
1983b). While X31 preferentially binds to the Neu Ac a, 2->6 Gal linkage and 
shows sensitivity to inhibition by y-inhibitors present in non-immune horse 
serum, receptor-binding variant viruses show increased affinity for 
oligosaccharides containing the a , 2 ^ 3  Gal linkage and are resistant to 
inhibition by horse serum.
Neutralising mAbs do not usually select for mutations in conserved 
residues that constitute part of the receptor binding site. In the present 
investigation, however, a majority of mAbs selected variant viruses that had 
amino acid substitutions within or proximal to the receptor-binding pocket. 
The question therefore arose as to whether these variant viruses also exhibited 
altered receptor-binding specificity.
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4.2. Results
4.2.1. Horse-senim inhibition assay.
In an initial attempt to determine the receptor-binding specificity of the 
valiant viruses, horse serum inhibition assays were performed with the TgM 
mutants. X31 and two laboratory variant viruses X31-HS (HAl 226 L->Q), 
and M l-9 (HAl 226 L->Q, 135 G->V) were used as controls. The results in 
table 9 show that variant m4.1 (HAl 135 G->R) behaved as wild type and was 
sensitive to inhibition by horse serum. X31-HS, M l-9 and TgM mutant m7.1 
(HAl 226 L->P, 145 S->N) showed complete resistance to inhibition whereas 
m l.l (HAl 135 G->R, 158 G->E) and m21.2 (HAl 135 G->R, 225 G-^D) 
showed partial resistance to inhibition by horse serum.
4.2.2. Binding Specificity for a,2->3 or a,2->6 Sialyllactosaminyl-BSA.
ELISA assays were performed with neoglycoconjugates and the 
specificity of the TgM mutants was compared with binding of X31 or X31-HS 
to o,2->3 or a,2->6 Sialyllactosaihinyl-BSA Bound virus was detected with 
biotinylated rabbit and/ or goat a-HA Ab and streptavidin-aUcaline phosphatase 
conjugate.
Figure 12 indicates that, X31 binds more effectively to the o,2->6 
substrate as compared to X31-HS for which there were base line values. 
However, X31 and X31-HS bound to the a,2->3 substrate equally well. With 
the exception of m21.2 (HAl 135 G->R, 225 G->D) showing preferential 
binding to a,2->6 Sialyllactosaminyl-BSA, the remaining TgM variant viruses 
m7.1 (226 L->P, 145 S->N) and mi l (HAl 135 G->R, 158 G->E) showed 
no significant difference in binding to either 0,2—>3 or 0,2—>6
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Table 9: Horse serum inhibition assay with
TgM mutants,
X31,
X31-HS (226 L->Q)
Ml-9 (226 135 G->V)
<  =  <20
Values indicate the reciprocal of horse serum dilution required to inhibit 
virus haemagglutination, as described in Methods, section 2.15.
Virus Horse Serum
X31 1280
226, 145 <
135,225 <
135,158 160
135 1280
Ml-9 <
X31-HS <
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Fig 12: Receptor-binding specificity of X31 and its variants for
sialyl 0-2,6 (a) or sialyl o-2,3 (b) N-acetyllactosaminyl-BSA in ELISA.
e  X31; ■  m-7.1 (145 S->N, 226 L-»P); ▲ m-21.2 (135 G->R, 225 
G-^D); T X31-HS (226 L ^ ) .
The procedures employed in this assay are described in detail, in Methods 
section 2.8.
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4.2.3. Summary
The receptor-binding specificities of the laboratory variants isolated 
in the study were investigated in parallel with X31-HS (HAl 226 L->Q), a 
variant selected by horse serum treatment. Variant m-7.1 (HAl 145, 226) 
and m-21.2 (HAl 135, 225) exhibited a similar specificity, to X31-HS, in 
their resistance to horse serum inhibition of agglutination, whereas partial 
resistance was seen for m-1.1 (HAl 135, 158), thereby confirming altered 
receptor fimction.
Then, I extended these studies to binding assays of variant viruses 
with ELISA plates coated with neoglycoconjugates either a, 2-3 (0-30 
jig/ml) or a , 2-6 (0-15 pg/ml) sialyllactosaminyl-BSA. Clear cut 
differences were found in the binding specificities for X31-HS, with base­
line values using the a , 2-6 substrate and wild type values for the a , 2-3 
substrate. X31 bound optimally to both substrates at approximately 
equivalent substrate concentrations (Fig 12; 10-15 pg/ml) suggesting that 
the binding assay was not sufficiently discriminating, although there was a 
two-fold difference in absorbance (for bound virus) between the two 
substrates.
In comparison with X31, variants m-7.1 and m-21.2 bound at 
significantly reduced levels to both a, 2-3 and a , 2-6 substrates. This 
reduction was most pronounced for m-7.1 (HAl 145, 226) in its binding to 
the a , 2-6 neoglycoprotein; and this is consistent with the known critical 
role of HAl 226 in conferring receptor-substrate specificity.
In previous reports, receptor-binding variants of influenza were still 
recognised by their selecting mAh in ELISA. Variant 21.2 exhibits such a 
phenotype and therefore qualifies as a receptor binding variant. 
Paradoxically, whereas m-7.1 was not recognised by its selecting mAb (in
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either HI or ELISA), it was negative by HI but positive in ELISA with 
mAh 21.2- (a receptor-binding variant phenotype).
Altered receptor-binding specificity was also indicated by the horse 
serum inhibition assays and mAb-selected variant viruses were resistant to 
inhibition with the exception of variant, HAl 135 G->R.
In the binding assay with 0,2-3 or 0,2-6 sialylglycoconjugates, 
binding of all variants was much reduced compared to X31. Thus, these 
assays indicate altered receptor binding specificity of the selected variant
viruses.
I l l
CHAPTER'S
The neutralising antibody response to a variant viral antigen 
in the face of concomitant immunity
112
5.1. Introduction
The recurrence of influenza virus infection is attributed primarily to 
changes occurring in the antigenic structure of the virus surface glycoproteins, 
especially of the haemagglutinin (HA) molecule (Gerhard, et a l, 1981). The 
human population is subject to sequential challenge with new variants of 
influenza virus and therefore mounts an immune response to limit infection. 
Haemagglutinin specific antibodies neutralise virus infectivity and as a 
consequence, provide selective pressure for the HA molecule to mutate (Wiley 
and Skehel, 1987).Thus the efficacy of an influenza virus vaccine is short 
lived.
Antigenic drift is a dynamic process and represents recurrent interplay 
of the human B cell repertoire and its diverse MHC genes, Ig genes and TcR 
genes with the newly emergent epidemic strain of influenza virus. Although a 
structural analysis of laboratory variants, selected with murine mAbs has 
provided considerable insight on the molecular basis for antigenic change, there 
is a major caveat in extrapolating these findings to the human repertoire. In the 
murine model, a virgin B cell is recruited into memory by a single challenge 
(and boost) with a reference laboratory isolate, whereas the human immune 
system is subject to recurrent infection and antigenic challenge.
Following infection with influenza virus, and subsequent re-infection 
with a variant strain, the individual is likely to mount both a secondary (cross­
reactive) antibody response and a primary response to altered antigenic sites. 
The immunodominance that is evident following primary infection of inbred 
mice, may (or may not )  have a profound influence on the neutralising antibody 
repertoire to a variant virus challenge.
To this end, I have attempted to establish a model system to investigate 
the neutralising antibody repertoire of CBA/ Ca mice to a recurrent infection
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with an influenza variant virus - a system that might be homologous to the 
human situation.
First, CBA/Ca donors were infected with X31 virus and after 
hemispknectomy, the neutralising antibody repertoire was analysed by 
production of mAbs fi-om the first half spleen. The same donors were then 
reinfected with a laboratory variant, with amino acid substitutions in regions 
that were known to be recognition sites for neutralising antibody and / or class 
n  restricted T cells, and a second batch of neutralising mAbs established from 
the other half spleen. This approach allowed me to study the neutralising 
antibody repertoire to a variant virus in the face of concomitant immunity.
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5.2. Results
5.2.1. Generation of HA specific B-cell hybridomas from CBA/ Ca mice 
after infection with X31 virus.
A brief summary of the procedures employed in the present 
investigation is as follows:
Mice were infected with X31 and, following recovery, half spleens 
were surgically removed to generate HA-specific B-cell hybridomas. The same 
mice were rechallenged with a variant virus A43 (Daniels et al., 1987) 
containing amino acid substitutions in regions recognised by both antibodies 
(HAl 158, 145 ), and T cells (del HAl 224-230) from CBA/ Ca mice. The 
remaining half spleens were used to generate a second batch of B cell 
hybridomas. The strategy is shown in fig 13.
A total of twenty neutralising mAbs (SGA series) from four individual 
donors were generated from the first half spleen. A majority of the mAbs were 
generated from donor 4 ( 8/20) and donor 3 (7/20)  ^As expected of a THl type 
response to virus infection, the predominant Ig isotype among these mAbs was 
IgG2a (14/ 20) , or IgA (3/20) as shown in the table 10.
5.2.2. Selection and sequence analysis of X31 variant viruses.
Four variants viruses were characterised and are referred to as the 
SCAM-3 series. As shown in the table 11 , two of four mutants, (m3-H7 and 
m3-G5) had the same amino acid substitution at position HAl 158 G->E 
which was previously shown to be an immunodominant site. m3-D5.1 had an 
amino acid substitution at position HAl 218 G->E, and m3-Gl 1 had a change 
at position HAl 188 N—>D.
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Fig 13: Protocol employed in hemisplenectomy.
(Mice were infected with X31 and half spleens were surgically removed to 
generate mAbs. Following re-infection with A43 (145,158, del 224-230), a 
second batch of mAbs were generated).
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Table 10: Isotype of CBA/Ca specific mAbs fi^ om four individual
donors in the secondary response to X31.
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Table 11; Recognition specificities of mAbs fi-om first half spleen as 
deduced by sequencing of the HA gene of X31 laboratory variants 
(SCAM).
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5.2.3. mAb reactivity for variant viruses by haemagglutination inhibition 
assay.
One of the main reasons for choosing the A43 variant for further 
infection was that it contained the HAl 158 change, and a deletion of HAl 
224-230 which is one of the predominant T-cell recognition sites for CBA/ Ca 
mice.
Table 12 indicates that a majority of mAbs (12/19) failed to recognise 
A43 virus (HAl 145 S->I, 158 G-^E and del 224-230). 8/19 mAbs did not 
recognise HAl 158 G->E and 4/17 failed to recognise A91 virus. Thus A43 
seemed to be a good candidate for re-infection.
5.2.4. Generation of B cell hybridomas after further infection with A43 
virus.
Mice that had undergone hemisplenectomy were re-infected with A43 
virus. Fusions were performed three days after the boost. Tissue culture 
supernatants of hybridomas were tested by HI assay and ELISA against both 
X31 and A43. The majority of the wells contained antibody activity in ELISA 
but were HI negative. Two wells showed low but significant activity in HI 
(with both X31 and A43) and were successfully cloned and expanded as 
ascities and named SCB-3 G1 and SCB-3 G8. Despite the low HI activity of 
hybridoma supernatant, respectable HI titres were observed for mAb 
containing ascitic fluid (table 13), but with preferential reactivity for the wild 
type, X31 virus.
mAbs were also tested by HI assay against variant viruses. Both mAbs 
recognised A91 (del HAl 224 - 230) and HAl 158 G->E equally well (either 
culture supernatant or ascitic fluid).
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Table 12; Haemagglutination inhibition assay (HI) with mAbs 
generated after X31 infection.
Variant A43; HAl 158 G -^E , HAl 145 S->I,
del HAl 224-230.
Variant A91; del HAl 224 - 230.
uiAbs HAl A43 A91 X31
158
1-D9 + . + +
1-ClO + +
3-D5 + +
3-F9 + + + +
3-F ll _ +/- +
3-H7 _ + +
3-G3 _ +
3-G ll + + + +
3-G5 . + + +
4-G ll + + +
4-G5 + + +
4-H2 + + + +
4-BlO + + + +
4-D9 ND +
4-Hl _ ND +
5-G8 _ + +
5-F4 - + +
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Table 13: HI titres of mAbs SCB-3G8 and SCB-3G1 from ascites
fluid.
HI titre expressed as the reciprocal of the dilutions required to
inhibit agglutination of turkey erythrocytes by 100%.
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5.2.5. Selection and sequence analysis of variants of A43 with mAbs from 
the second half spleen.
(a). Variant selection with mAh SCB-3 Gl.
mAb B-3 Gl was used to select a variant of A43 and sequence analysis 
of its HA gene showed amino acid substitutions at two more residues: HAl 
145 I-»S, 189 Q->K (Table 14). As already mentioned, A43 differs from X31 
at HAl 145 S ^ I  and the selection with mAh B-3G1 had resulted in a 
reversion to wild type at this position.
(b). Variant selection with mAh SCB-3 G8.
mAb SCB-3 G8 selected an À43 variant with two further amino acid 
substitutions, HAl 196 V->A 145 I->8 (table 14). Interestingly, both mAbs 
from the second half spleen selected variant viruses that had reverted to wild 
type at HAl 145.
5.2.6. Selection and sequence analysis of X31 variants with mAbs from 
second half spleen.
(a) Variant selection with mAh SCB-3 Gl.
mAb B-3 G l, generated after further infeaion with A43, still 
recognised X31 in HI tests and it was of interest to obtain a definitive 
assignment of recognition specificity. Variants of X31 were selected, and their 
genes sequenced. Table 15 shows that variant m3-Gl.l has amino acid
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substitutions at three different positions, HAl 193 S->N, 198 A->E, 226 
L->R.
The amino acid substitution at HAl 226 was of some interest, in view 
of OUT earher findings with human transgenic p  chain mAbs, and the role of this 
residue in receptor binding specificity. Thus, to confirm recognition specificity, 
mAb 3-Gl was used to select further laboratory variants of X31. Further 
selection produced a variant (m3-Gl-C) with amino acid substitutions at HAl 
198 A->E, 223 V->I. Again, the precise specificity of this mAh could not be 
deduced since the variant had two amino acid substitutions, with HAl 198 
A—>E being common change to both mutants. Therefore, the mAh was used 
for a third selection and sequence analysis of the HA gene showed a single 
amino acid substitution at position HAl 198 A->E.
Thus, following selection with mAh B-3 Gl, two of three variants had 
more than one amino acid substitution in HAl.
(b) Variant selection with mAb SCB-3 G8.
The variant virus selected with mAh SCB-3 G8, had a single amino 
acid substitution at position HAl 198 A—>E. Thus, mAbs generated after 
sequential infection with A43 seemed to be specific for HAl 198, but what is 
the possible significance (if any) of concomitant changes at HAl 193 and 226, 
or 223? I will later speculate that there are distinct similarities to the 
recognition specificties shown by low affinity mAbs fi"om human transgenic 
mice.
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Table 14 : Recognition specificities of mAbs generated from the
second half of the spleen deduced by sequencing of the HA gene of A43 
variants.
Variant A43: HAl 158, 145, del 224-230
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Table 15; Recognition specificities of mAbs generated ft^ om the second 
half of the spleen, deduced by sequencing of the HA gene of X31 laboratory
variants.
♦mAb SCB-3 Gl was used three times for the separate selection of escape 
mutants.
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5.2.7. Summary.
In this section, a comparison was made of the neutralising antibody 
repertoire of individual CBA/Ca mice to natural infection with X31 (by 
hemisplenectomy and hybridoma production) followed by re-challenge with a 
variant virus, A43 that differed form wUd type at HAl 145, 158, del 224-230), 
and further hybridoma isolation. The recognition specificities of neutralising 
mAbs, obtained fi-om the first and second hybridoma fusion were determined 
by selection of variants for both X31 and A43. A majority of mAbs, isolated 
following X31 infection, failed to recognise variants HAl 158 or A43, and 
selected X31 variants with single residue changes at either HAl 158 or HAl 
218.
In contrast, mAbs obtained after re-challenge with A43 still recognised 
wild type and selected X31 variants with residue changes at HAl 193 S->N, 
198 A->E, 226 L ^ R  or HAl 198 A->E, 223 V-^I or HAl 198 A->E. 
Interestingly, the same mAbs selected A43 variants with changes at HAl 145 
I->S, 189 Q->K or HAl 145 I->^ S, 196 V->A. There are two significant 
points to note fi-om these findings. First, the prevalent selection of variant 
viruses with multiple substitutions using mAbs established from the second half 
spleen after re-infection with A43. Secondly, the residue changes identified in 
X31 variants, selected by the “second-set” mAbs, have never been reported (in 
this laboratory) for mAbs established from CBA/Ca mice following primary 
infection with X31.
I conclude that a different neutralising Ab repertoire may be recruited 
following recurrent infection with influenza variant viruses, and thus may be of 
some relevance to the human situation, in which there is selective pressure for 
antigenic variation from herd immunity, and multiple exposure to infectious 
virus.
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CHAPTER-6
Novel specificity of a neutralising mAb front a BALB/c 
donor, elicited by natural infection
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6.1. Introduction
Neutralising mAbs of the IgG subtype, are of moderate afiOnity and do 
not usually select for mutations within the conserved residues of the HAl 
subunit. The X31 variants selected for by mAbs from Hulg p chain transgenic 
mice are an obvious exception and may be a consequence of low affinity IgM 
responses. Moreover, a mAb of the IgG2b subtype established from a BALB/c 
donor following X31 infection had selected a variant virus HAl 226 L->Q, 
135 G->V (Dr. Claire Smith, unpublished finding). The selecting antibody 
failed to recognise its variant in both HI and ELISA qualifying it as an 
antigenic variant. HAl 226 L->Q has featured recently in H3 isolates (e.g. A/ 
BEDING/ 93), but there has been no evidence to indicate antibody recognition 
of conserved residues within the receptor-binding pocket.
The purpose of this study was to investigate the recognition specificity 
by further selection and sequencing of variant viruses produced by this 
particular antibody and to investigate if there was any affect on receptor- 
binding specificity.
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6.2. Results
6.2.1. Haemagglutination-Inhibition ( HI) assay.
mAb B 1-9.1 (Dr. C A Smith; unpublished results) was tested by HI 
assay agmnst a panel of laboratory variant viruses with known single or double 
amino acid substitutions within the HAl subunit (table 16 ). The results show 
that mAb B 1-9.1 did not recognise its selected mutant HAl 226 L-^Q, 135 
G->V, or HAl 135 G-^R, 158 G-»E. The same mAb, however, recognised 
HAl 135 G->R, that was included in the assay (due to the unavailability of 
HAl 135 G->I). The remainder of the laboratory variants were recognised as 
well as X31.
6.2.2. mAb reactivity for laboratory variant viruses in ELISA.
Since mAb B 1-9.1 had selected a variant virus with an amino acid 
substitution in a conserved residue of the receptor-binding pocket (HAl 226 
L->Q), it was important to determine whether it recognised its selected variant 
in ELISA (Fig 14). The mAb tailed to bind to the variant, thereby qualifying it 
as an antigenic mutant. HAl 135 G->R, 158 G-^E was also not recognised, 
however, the mAb bound well to HAl 226 L - ^ ,  HAl 135 G-^R, and HAl 
158 G->E (somewhat reduced titre for 158 G->E).
6.2.3. Further selection of X31 variant with mAh Bl-9.1.
To obtain a definitive assignment of recognition specificity, Bl-9.1 was 
used to select further X31 variants. Six mutants were characterised and named 
CCMl series (table 17). All six variant viruses had the same two changes, 
HAl 135 G-^R, 158 G-^E The amino acid change at HAl 135, however, 
differed fi’om that obtained following the initial selection (HAl 135 G->V).
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Table 16: Haem^glutination inhibition assay (HI) with mAb Bl-9.1
and laboratory variant viruses.
HI titre expressed as the reciprocal o f the dilutions required to
inhibit agglutination of turkey erythrocytes by 100%.
< less than 100.
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Fig 14: mAb Bl-9.1 recognition specificity for variant viruses by
ELISA
Reactivity with X31 (□); or 158 ( • ) ;  or 226, 135 (V); or 226 (O); or 135 
(A).
The ELISA procedures are described in Methods section 2.7.
1 . 0 1
Ec
lOo  
c5
0)
Üc
CO
JD
o
CO
J Q<
0 .7 5
0 .5 -
0 .2 5 -
3 4
mAb dilution
T h o m a s  5  7 / 1 1 / 9 6  N P
131
Table 17: Recognition specificity of mAb Bl-9.1.
All variant viruses were selected at different times and are therefore not 
sibling isolates.
BB
ÎÎI»
B
•io VOVO VO00 VO VOON VOVI
3
MD
3
VI w 
0 0  V I
0  o
1  i
V I
00
w
V I
i t
V I w  
0 0  V I
n
V I
00
w
V I
V I w  
0 0  V I
o  o4- itn ?5
V I w  
0 0 .  V I
0  o
1  i
K ) Sw to >
V I ON
O y &
90
< p S99fB
V I
V I 0 0o  o  
>  >
V I
V I o oo  o  
>  >
V I ^  
V I 0 0o  o  
> >
V I
V I 0 0
?
V I ^  
V I 0 0o  o
Î  Î  > >
V I 4 k  
V I ooo  o
Î
s  — ^
O H
4 i
z
IMeS'
§
s*
5
132
6.2.4. Selection and sequence analysis of further variants of either HAl 
135 G->R or HAl 158 G ->£.
The HI and ELISA results had shown that Bl-9.1 recognised both 
HAl 135 G-^R and HAl 158 G->E variants suggesting that amino acid 
substitutions at both 135 G—>R and 158 G->E were necessary to abrogate 
antibody recognition.
Thus, mAb Bl-9.1 was used to select variants of HAl 135 G->R 
Three mutants were sequenced and named the PIB series. All three variant 
viruses had substitutions at three residues, HAl 135 G->R, 158 G->E and 251 
L-^I (table 18).
A further variant of HAl 158 G->E was also selected and sequenced 
and had changes at HAl 158 G->E, 146 G->D (table 19).
6.2.5. Horse Serum inhibition assay.
Horse serum inhibition assays were performed with Bl-9.1 selected 
variants to determine their receptor-binding specificity. As indicated in table 
20, X31 and HAl 135 (used as controls), were sensitive to inhibition by horse 
serum. In contrast, HAl 135, 158, HAl 146, 158, and HAl 135, 226, all 
behaved as the receptor-binding variant (HAl 226) and showed resistance to 
inhibition, thus, indicating altered receptor-binding phenotype.
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Table 18. Selection and sequencing of variants of HAl 135 (G->R)
using mAb Bl-9.1. The further residue changes (HAl 158, 251) are 
indicated.
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Table 19: Amino acid residue change following mAb-9.1 selection of
X31 variant (HAl 158).
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Table 20: Horse serum inhibition assay with Bl-9.1 selected variants
of X31 or HAl 135 (G—>R), or X31-HS (226 L—>Q). Values represent 
the reciprocal of horse serum dilution required to inhibit haemagglutination 
(Materials section 2.15).
< less than 20.
Virus Horse Serum
\X31 1280
226 <
135,158 80
146, 158 <
135 1280
226, 145 <
135, 225 160
135 1280
145 20
226, 135 <
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6.2.6. Summary
A neutralising mAb of the IgG2b isotype (Bl-9.1) isolated and 
characterised by other members of this laboratory had selected an X31 variant 
HAl 135 G-^V, 226 L->Q. In view of my findings for mAbs fi-om Hulg 
transgenic mice, which had selected variant viruses with similar residue 
changes within the receptor binding pocket, I wished to determine whether this 
was a consistent phenotype for variants selected with this mAh.
A further series of six variant virus selections was made with mAb Bl- 
9.1. All variant viruses contained the same residue changes HAl 135 G->R, 
158 G->E. However, the selecting mAh Bl-9.1 still recognised X31 variants 
containing single residue changes at HAl 135 or 158, indicating a requirement 
for mutations at two distinct sites to abrogate mAb neutralisation. Advantage 
was taken of this finding to select further variants of HAl 135 G->R or HAl 
158 G->E:
mAh Bl-9.1 selected three further variants of HAl 135 G—>R which 
were cloned and their HA genes sequenced. Each variant virus contained the 
same substitutions at HAl 135 G—>R, 158 G->E, 251 L—>1.
mAb Bl-9.1 selected a further variant of HAl 158 G-^E which had an 
additional residue change at HAl 146 G->D.
Resistance to horse serum inhibition in HI assays confirmed that variant 
viruses HAl 135, 226 or HAl 135, 158 or HAl 146, 158, which had been 
selected for by mAb B l-9.1, had altered receptor-binding specificity.
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7. Discussion
The initial aim of the thesis was to investigate the influence of afiinity 
on the recognition specificity of the neutralising antibody repertoire for 
influenza virus HA using a novel murine transgenic model in which IgM to IgG 
class switching and concomitant somatic hypermutation/ affinity maturation 
were absent. Use was made of transgenic mice containing a human Ig H 
minigene, and disrupted murine Cp to generate neutralising IgM mAbs which 
were used to select laboratory variants of X31. Sequencing of the HA genes of 
variant viruses indicated that several amino acid substitutions were within 
conserved residues that constitute part of the receptor binding pocket and 
which affected receptor binding specificity. With hindsight, the initial proposal 
by Fazekas de St Groth, in the 1970’s, that low affinity Abs preferentially 
select adsorptive (i.e. receptor binding) mutants is now seen to be remarkably 
prophetic, and based on work with polyclonal Abs, in the absence of structural 
information on the HA molecule. Given the most recent and extensive 
structural information available for influenza virus HA, obtained from 
crystallographic studies, and the sequence analysis of the HA genes of the 
variant viruses, it is now possible to correlate changes in receptor binding 
specificity with 3-D structure.
The conclusion that I wish to propose in this thesis, is that Abs of low 
affinity may preferentially select for receptor binding variants; and a similar 
situation may pertain for in vitro situations in which laboratory variants are 
selected using sub-neutralising levels of antibody. Such bias in variant 
selection, in the absence of an optimal level of high affinity Abs may be of 
some relevance to herd immunity and immune evasion by influenza viruses.
Our understanding of influenza virus HA antigenicity has been 
significantly advanced on two fi-onts by (a) crystallographic studies on the 
structure of B-HA and (b) the use of murine mAbs to select, in vitro, antigenic
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variants. From the immunologist’s standpoint, however there are two 
important caveats.
First, mAbs are usually established following virus (or viral protein) 
immunisation of a naive donor (not previously exposed to multiple infections 
with influenza virus - as is the case in humans). Secondly, the majority of mAbs 
are of the IgG class, of moderate affinity, and produced several weeks or 
months after primary immunisation - thereby ensuring extensive B-memory cell 
development.
The human Ig H transgenic mouse provides a novel model system to 
investigate the influence of antibody affinity on recognition specificity, in the 
absence of class switching fi'om IgM to IgG. In a wild type mouse, 
immunisation or infection with influenza virus results in class switching by day 
6; and there is no experimental procedure to regulate (or restrict) affinity 
maturation.
The second part of the thesis was concerned with the influence of 
concomitant immunity on the neutralising antibody response to a variant virus, 
in an attempt to address the question of multiple exposure to infectious virus, 
as is the case in the human situation. In both model systems (transgenic and 
hemisplenectomy) I have found that mAbs preferentially select for variant 
viruses containing multiple residue changes, including substitutions within 
conserved residues of the receptor binding pocket.
The advent of mAb technology, for the selection and subsequent 
sequencing of laboratory variant viruses allowed a definitive assignment of 
neutralising antibody recognition sites to the 3D structure of Bromelain 
cleaved HA, as deduced fi-om crystallographic studies. In most instances, 
laboratory variants had been selected for by mAbs of the IgG class (and of 
moderate to high affinity due to maturation of B cell memory in the interval 
following immunisation, and subsequent boosting). Such laboratory variants, in 
most instances differ fi'om wild type by a single amino acid substitution in one 
of the five major antigenic regions known to change in natural H3 isolates.
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The model system that I have investigated differs from such an 
approach in one important respect- affinity maturation may have been 
compromised. As a result a series of novel laboratory variants have been 
characterised that differ from wild type virus by two or more amino acid 
substitutions in the HAl subunit, including residue changes in conserved 
positions corresponding to the receptor-binding pocket.
It is generally considered that conservation of residues within the 
receptor binding site are a consequence of function: structural alterations 
within the receptor binding site affect specificity and therefore abrogate virus 
infectivity. Moreover, it has been argued e.g. for the rhinovirus receptor site, 
that the physical dimensions of the pocket (or canyon) might prevent 
accessibility to neutralising antibody- the so called “canyon 
hypothesis”(Rossmann, et al., 1985)
However, recent crystallographic information for both influenza B-HA 
complexed to Fab fragments of a neutralising mAb (specific for HAl 157) 
(Bizebard et al, 1995) and human rhinovirus HR-14 capsid Fab complexes 
(Smith et al, 1996) indicate that there can be a close contact between the CDR- 
3 loop of the Fab chain and the conserved residues of the pocket. Indeed, in B- 
HA complexed to Fab, the CD3 loop resembles a finger projecting directly into 
the pocket and contacting many of the conserved residues. One may conclude 
that conservation of binding specificity and function, rather than accessibility to 
antibody is the primary determinant ensuring that these critical residues are not 
subject to immune selection.
Although this thesis was initiated from an immunological perspective 
(of the laboratory), and I do not consider myself sufficiently knowledgeable to 
offer a critical appraisal of the structural implications of document findings, 
due consideration will be given to the molecular structure of HA as it relates to 
receptor structure and function, and the residue changes reported for variant 
viruses in this thesis.
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To reiterate, the hallmark of the immune response is its specificity. The 
germline encodes a large but selected repertoire of antibody binding sites which 
is constantly displayed in a population of B lymphocytes with a rapid turnover. 
The large number of possible V-D-J segment combinations and the junctional 
imprecision of the rearrangement process give an individual mouse the ability 
to create fi'om 10* to lO" different antibody structures (Gearhart and 
Bogenhagen, 1983; Tonegawa, 1983). Because each B cell uses its unique Ig 
structure as its surface receptor for antigen, and because uptake of antigen by 
B cells is an initial step in T cell-dependent B cell responses, immunisation with 
an antigen results in selective stimulation of only a small fi-action of B cells 
fi’om a large pool of available specificities.
Specificity, however, is directly correlated with the affinity of the 
antigen-antibody interaction. In a normal individual, the initial antibody 
response is primarily of the IgM class which is rapid and tails off quickly. IgM 
antibodies generally express germ-line determined variable regions that have 
not yet been modified by somatic mutation and so they tend to bind antigen 
with low affinity. The low frequency of substitutions in IgM antibodies 
suggests that the mutational mechanisms do not occur in pre-B cells during the 
joining of V, D and I gene segments. By day 4-6, the frequency of antigen 
specific B cells increases about 1000-fold and they undergo class-switching 
from IgM to IgG and IgA. The antibodies produced at this stage react more 
efficiently, forming stable complexes with the antigen.
A structural basis for these changes emerged from studies using 
hapten-protein conjugates as a model system. Haptens such as 2,4- 
dinitrophenyl (DNP), 2-phenyl oxazolone (phOx), or phosphorylcholine elicit a 
hapten specific immune response when conjugated to a large carrier molecule. 
For example, DNP conjugated to bovine serum albumin (BSÂ) or ovalbumin 
enables the immune system to elicit a hapten specific secondary response on 
subsequent challenge with the hapten, on an unrelated earner, It was noticed 
that antibodies isolated from serum 1-2 weeks after immunisation, bound e-
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DNP-lysine with low intrinsic affinities (10^-10* M**) and antibodies isolated 
after a few months bound this ligand with affinities around 10 -^10* M** (Eisen 
and Siskind, 1964). After many months, when serum antibodies had fallen to 
near background levels, another exposure to the antigen (booster 
immunisation) resulted in prompt appearance of the antibodies with high 
affinity (Siskind and Benaceraff, 1969).
With the advent of mAh hybridoma technology, Milstein, Rajewsky and 
colleagues were able to establish the molecular basis for affinity maturation and 
directed their studies towards the more homogenous responses against 
haptens. Extensive sequence analysis of the heavy and light-chain mRNA of 
hybridomas immunised with a specific hapten has helped us to understand the 
interplay between genetic and selective events during the onset and maturation 
of the immune response.
Kaartinen et al., 1983, determined the sequence of both heavy and light 
chains of 15 mAbs obtained 7 days after immunisation, against the hapten 
phOx, coupled to chicken serum albumin (ph-CSA). The response was 
particularly restricted to IgGl class with an affinity of 10'^  Mol'\ Most of the 
anti-oxazolone antibodies had the same Vh and Vt combination encoded by a 
pair of germline genes, Vy-Oxl and Vk-Oxl respectively: 11 out of 15 
hybridomas (73%) expressed V h -0 x 1  and Vk-Oxl. Minor differences in the 
sequences were concentrated in the D region and at the D-Jh and Vk-Jk joining 
boundaries (Kaartinen, et al., 1983). One week later (14 days after the primary 
injection) most antibodies still expressed. similar, but no longer identical 
sequences: 6 out of 11 (54%) expressed that combination, suggesting a high 
degree of somatic mutation. After secondary immunisation, only 4 out of 23 
lines were related to the V h -0 x 1  with Vk-Oxl combination, indicating a shift 
to a new germline H-L chain combination and a Vh subgroup emerged which 
had not been detected at earlier stages of response (Berek, et al., 1985). Thus, 
although somatic mutation is a major factor in maturation of the immune 
response to phOx, the shift towards alternative germline gene expression is
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equally important in further improvements in antibody affinity at later stages of 
the response.
The observations made on the maturation of the immune response to 
phOx are generally consistent with those made in other hapten systems. Thus, 
primary antibodies to nitrophenylacetate have \  chains and are largely 
unmutated, whereas hyperimmune antibodies have k chains and are somatically 
mutated, and display increased affinity for the hapten (Bothwell, et a i, 1981).
A detail analysis of genes and proteins that participate in the murine 
immune response to phosphorylcholine was also documented by Malipiero et 
al., 1987. 37 out of 38 antibodies were encoded by 1 Vh gene of the SI07 
subfrmily, and 3 Vk genes,VkT15 of the Vk22 subfamily, VkM3 from the Vk8 
subfamily, and Vk 167 from the Vk 24 subfamily (Malipiero, et a i, 1987). No 
mutations were detected in those genes until the second week after 
immunisation. Sequence analysis of anti-PC antibodies showed a striking 
correlation between the presence of mutation and antibodies that had 
undergone class switching. No mutation was found in 18 heavy and light chains 
from IgM antibodies, whereas mutation was evident in 7 out of 13 chains in 
IgG3, 13 out of 24 chains from IgGl, and 8 out of 18 chains from IgA 
antibodies. M ost o f the mutated antibodies had higher affinity fo r antigen than 
their gerrriline counterparts, which suggests that the major role o f somatic 
mutation is to increase affinity rather thati to create new specificities.
Antibody responses to proteins, and viruses, however, are different 
from anti-hapten responses, probably because of the antigenic complexity of 
proteins. Thus, in contrast to the progressive changes seen with the anti-hapten 
antibodies, a relatively rapid increase in the average antibody affinity was 
observed against hen egg lysozyme (HEL) (Newman, et a l, 1992). A majority 
of the antibody response was either IgGl or IgG2a while IgM antibodies were 
rare even in the primary response. The overall affinity did not increase further 
during the course of the response which suggested that those mAbs 
represented a population of Ag-selected antibodies that had already undergone
143
somatic mutation during initial antigenic stimulation. Does this mechanism also 
apply in virus infection where high affinity neutralising antibodies are essential 
for protection?
Recent studies by Zinkemagel and colleagues, using vesicular stomatitis 
virus (VSV) in a murine model system reported rapid onset of high affinity 
serum IgG responses and “on rate” kinetics coincident with viral clearance 
(Roost, et a i, 1995). IgG antibodies were evident 6 days after the infection 
and the values did not increase in response to repeated booster injections 
spread over 150 days. Memory levels of neutralising anti-VSV IgG titres 
(between 1:80,000-1:320,000), remained stable within the range of 2-4 for >6 
months, and did not increase by more than a factor of 4-8 after booster 
injections compared with the response after a single infection. Thus, the quality 
of the response did not improve further with time, or re-exposure. The direct 
implication is that binding a target antigen rapidly may be as important as the 
thermodynamic stability o f the resulting antibody-antigen complexes in 
limiting pathogen growth.
It can be speculated that since VSV is a replicating virus with repetitive 
copies of its antigenic glycoprotein, it accelerates the tempo of affinity 
maturation, generating high affinity B cells by day 6. However, high affinity 
antibodies were also obtained by day 7 after immunisation with lysozyme 
which is a non-replicating protein antigen (Newman, et a l, 1992). Thus, there 
must be some other reasons for such a response. It could be the type of virus 
that has caused infection or more importantly, the route of infection. We do 
know fi'om previous studies that infection with live virus elicits a memory 
repertoire different to the response following immunisation or vaccination with 
attenuated or dead virus (both with respect to longevity and specificity).
Thus, previous studies in this laboratory have shown, that the immune 
response to influenza HA following natural infection elicits an extremely 
narrow window of specificity, and immunodominance is observed in different 
strains of mice (Patera, et a l, 1995; Smith, et a l, 1991). Immunodominance
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could not be attributed to Vh or Vl gene usage since the individual’s response 
to a single antigenic site was derived from a minimum of 3-6 progenitor cells 
(Patera, e ta l ,  1995).
These studies contrast with several other reports where a highly diverse 
response against HA has been documented (Caton, et al., 1986; Clarke, et al., 
1985; McKean, é ta l ,  1984; Staudt and Gerhard, 1983). It is important to note 
that such diversity was achieved following immunisation with the virus. For 
example, analysis of secondary haemagglutinin site (HA-Sb) specific mAbs 
isolated from mice on day 24 were highly diverse in contrast to primary 
antibodies that were structurally and functionally similar. This increased 
diversity in the secondary response was caused by the use of a larger repertoire 
of Vh and Vk genes and to somatic mutation. The effect of somatic mutation 
on specificity was such that even though secondary responses were oligoclonal, 
virtually every antibody had a unique antigen binding site and fine specificity 
(Clarke, era/., 1985).
Balkovic et al., 1987 found that immunisation with inactivated 
influenza virus or viral protein elicited an IgG response with a subclass 
distribution similar to that of anti-protein antibodies, that is, predominantly yl. 
Infection of CBA/Ca or C3H/HeN mice with virulent or non-virulent influenza 
virus elicited high y2a, low yl/y2b and very low y3 serum antibody levels 
typical of antiviral responses. Surprisingly, immunisation with inactivated virus 
also gave high y2a, moderate y2b and very low yl/y3 profiles, whereas 
immunisation with HA/NA protein gave a typical protein isotype profile of 
high yl, low y2a and very low y2b/y3 serum antibody (Balkovic, et a l, 1987).
Hocart et al., 1989, found the antibody responses to H3 subtype virus 
to be predominantly of the y2a subclass irrespective of the route of inoculation, 
but the magnitude of response varied with the route and schedule of 
inoculation and dose (Hocart, et a l, 1989). The response to intranasally 
administered HA is much h i^er than i.p., suggesting the i n. route can give 
better protection from influenza virus than the i.p. route due to the
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amplification of antigen during virus growth or induction of secretory IgA 
(Coutelier, et a l, 1987). Inraperitoneal and i.v. immunisation elicited 
predominantly y2a antibodies. No y3 antibodies were detected in the primary 
response to i.v. virus. The primary response to i.p. HA on day 3 consisted of 
y2a and y2b antibodies only. By day 7, yZa, y2b, yl and y3 were all equally 
represented and by day 14, following a secondary boost, yl antibodies 
exceeded y2a, and y2b and y3 were absent from serum antibody. y3 was also 
absent fi^ om the early primary response to i.v. HA, all isotypes were detectable 
by day 7 but y2a predominated, and by day 14, in the secondary response, the 
order of antibody titre was y2a > yl> y2b> y3.
The y2a antibodies predominate regardless of route of inoculation of 
influenza virus (i n. verses i.m.) in serum and lungs of CBA/Ca mice. However, 
the response to inactivated virus consists of all four y isotypes. BALB/c have 
higher titres of yl/y2a than C57BL/6 which has the highest titres of y2b. 
Neutralisation activity of the différent isotypes also varies with strain. For 
example, yl is twice as effective as y2a, which is twice as effective as y2b in 
BALB/c, but in C57BL/6, y2a and y2b are more effective than yl and y3, and 
in CBA/Ca mice, y2a has twice the neutralising activity of y2b.
The present investigation, and previous studies in this laboratory have 
shown that secondary antibody responses in CBA/Ca, BALB/c or BALB/k 
mice to be predominantly of the y2a, subclass (Smith, et a l, 1991),which is a 
characteristic trait of most viral infections in the mouse (Coutelier, et a l, 1988; 
Coutelier, et a l, 1987) and may illustrate the influence of antigen-specific CD4 
T cells: Thl cells secrete y-IFN, which enhances y2a, synthesis in vitro 
(Snapper, et a l, 1988), and has been shown to preferentially induce y2a 
production (Mosmann and Coffinan, 1989).
For neutralising antibodies to VSV or rabies virus, high affinity 
antibodies are essential at an early stage of infection since slow affinity 
maturation may allow chronic or severe systemic infection and prolonged
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transmission of the virus. In contrast, influenza virus does not establish 
systemic infection, and is restricted to the respiratory tract due to a 
requirement for apical budding from epithelial cells into the bronchial lumen 
(Roth, 1983). Consequently, host IgM antibody responses may not be a 
significant determinant of immune protection and /or antigenic variation. Thus, 
protection from live virus challenge is associated with rapid clearance by both 
secretory IgA and serum IgG (by transudation) so that by day 6 post infection 
there is no significant lung titre for virus. This is also associated with rapid 
class-switching.
The most detail studies to determine the dynamics of class specific 
antibody responses to HA in serum and nasal secretions have been reported by 
Murphy and his colleagues, who used live attenuated vaccines. Serum antibody 
responses typical of primary viral infections were detected in naive children 
using the ELISA technique (Murphy, et a l, 1982). IgM, IgA and IgG 
antibodies appeared in the serum within two weeks after inoculation of virus. 
The maximum serum IgG response was detected at approximately six weeks, 
while IgM and IgA antibody levels declined after two weeks. In nasal 
secretion, IgA was the predominant antibody and was present in the majority 
of individuals within two weeks of inoculation. IgG and IgM responses 
occurred less frequently and with low titres.
Changes in receptor binding site structure and function:
The selection of influenza virus variants with altered receptor binding 
properties has been reported previously by several groups. For the most part, 
such variants had either been selected for on the basis of their resistance to 
glycoprotein inhibitors of viral infectivity (Rogers, et a l, 1983b), or because of 
their ability to grow in various host cells (Burnett and Bull, 1943; Cohen and 
Biddle, 1960; Crecelius, et a l, 1984; Schild, et al., 1983). However receptor 
binding or adsorptive mutants have also been reported following selection with 
sub-neutralising levels of monoclonal antibodies (Daniels, et a l, 1987; 
Temoltzin-Palacios and Thomas, 1994; Yewdell, et a i, 1986).
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Yewdell et al, (1986) reported the selection of mutants by sub- 
neutralising levels of a mixture of monoclonal anti-HA antibodies. The 
antibody mixture contained at least two antibodies specific for each of the four 
PR8 HA antigenic sites. Although, the mutants did not differ from wild type 
antigenically, variation was observed in the ability of individual antibodies to 
inhibit mutant and wild type viruses firom agglutinating chicken erythrocytes. In 
contrast, very small differences were observed when human erythrocytes were 
used. That difference was probably due to the altered interaction of the virus 
with the cellular receptors and not due to the differences in antigenicity; Two 
of the residues (HAl 185 and 231) in the variants were found to be located 
near the receptor-binding site and could directly alter binding. The third residue 
(HAl 244) was located at the trimer interfhce. The variants were also able to 
agglutinate erythrocytes which were treated with twice the amount of 
neuraminidase needed to prevent agglutination by the wild type virus. Thus, it 
seemed that the antibody selected variants had higher affinity for cellular 
receptors.
Daniels et al, 1987, reported an IgGl mAh (HC63) that was broadly 
cross-reactive for a majority of natural H3N2 isolates. A number of variants of 
X31 and o f a receptor-binding mutant o f X31 (X31-HS. HAl 226 L—>Q) were 
selected by that antibody in eggs and in MDCK cells. Those variants principally 
involved substitutions in positions HAl 218 G->R, HAl 193 S->N, 226 L—>P, 
or deletion of HAl 224-230 (RGLSSRI). In most instances, the variant was 
recognised by the selecting antibody in ELISA although there was resistance 
to Ab neutralisation, or haemagglutination inhibition. The variants also showed 
altered receptor binding properties compared to X31: they either agglutinated 
erythrocytes containing the SA a  2,3 Gal linkage (HAl 218 G—>E), or showed 
resistance to inhibition by a 2-macroglobulin (del HAl 224-230; HAl 193 
S->N, 226 L->P) or exhibited transient haemgglutination of all derivatised 
cells.
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Temoltzin-Palacios and Thomas (1994) employed a somewhat different 
approach to select receptor-binding variant viruses: certain HAl antigenic 
residues (63, 144, 158, 193) were found to be immunodominant in the 
neutralising Ab response of CBA/Ca mice to X31 infection. Following 
sequential mAb selection, in ovo a variant of X31 was obtained (IMUT-4) with 
substitutions at each of these positions, and was used to infect naive CBA/Ca 
recipients, and to obtain neutralising mAbs. Each of the mAbs failed to select 
antigenic variants of IMUT-4 but, following treatment with sub-neutralising 
levels of mAh, a receptor-binding mutant was obtained with two further 
changes (HAl 190 E->D, 226 L->Q). The variant was resistant to horse serum 
inhibition and was still recognised by the selecting mAb in ELISA It is of some 
interest that these same two residue changes (HAl 190, 226) have been 
reported in recent H3 isolates (e.g. BEIGING/92 - World Influenza Centre; 
NIMR).
The selecting mAb used in this study still recognised X31, and was 
used to select an X31 variant virus. This differed from wild type by a single 
residue change, HAl 155 Thr->De, which also conferred altered receptor- 
binding specificity (for N-glycolylsialic acid of horse RBC).
The structure of the receptor binding pocket was discussed in the 
introductory section (1.8.7 and fig 5) and I have indicated, in a space filling 
model (Fig 15), the topographic relationship of residue changes in the 
laboratory variants m 7.1 (HAl 145, 226) or m-21.2 (HAl 135, 225) or m-1.1 
(HAl 135, 158) or m-4.1 (HAl 135) (fig 15). Residues 134 -138 form the 
right side of the site and residues 224-228 form the left side and the bottom of 
the binding site is formed by Tyr 98 and Trp 153. The residues Glu 190, Leu 
194 project down f r o m  a short a-helix which, together with His 183 and Thr 
155 define the rear of the depression. What residue changes therefore, within 
this region of the molecule, affect receptor specificity?
It should be emphasised that, despite a consistent finding that antigenic 
residue changes are located proximal to the binding pocket, some antigenic
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Fig 15; Space filling model indicating molecular location of the
amino acid substitutions in the laboratory variants mentioned in this thesis.
■9
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residue changes do affect receptor-binding specificity. For instance, the drift 
substitution HAl 155 Thr->Tyr in natural isolates confers increased affinity for 
N-glycolyl sialic acid residues, present on horse RBC. Furthermore, Temoltzin- 
Palacios and Thomas (1994) have reported a laboratory variant of X31, HAl 
155 Thr->Ile that is able to agglutinate horse RBC; and the same residue 
change has occurred in natural H3 isolates (CAEN/83 or SOF/84; data from 
the World Influenza centre, NIMR). Similarly, HAl 158 G->E is a defined 
antigenic site for both laboratory variants and natural isolates (e.g. TEX/77) 
and thus residue change differentially affects susceptibility (in agglutination 
assays) to periodate treatment of RBC.
Exposure to mild periodate treatment (in the absence of light) 
selectively cleaves cis-hydroxyl groups, present in the N-glycan side chain; and 
attacks terminal sialic acid residues, at the C7-C8 cishydroxyl tail, thereby 
effectively reducing the quantity of available sialic acid residues that can 
participate in agglutination reactions. (An alternative procedure would have 
been mild NANAse treatment of RBC).
Rather than antibody selection, inhibition by equine armacroglpbulin 
was used to select for a receptor-binding variant and which was found to differ 
from wild type virus by a single residue change HAl 226 L->Q (large non­
polar to large polar residue). Changes in receptor-binding specificity were 
confirmed by altered specificity for a , 2-3 and 0,2-6 sialyl derivatised RBC in 
agglutination assays. The crystal structures of both wild type and variant HAs 
complexed to sialyllactose have been deduced by Weis et al (1988) and the 
authors conclude that minimal changes have occurred in the receptor pocket so 
as to accommodate the introduction of a large polar residue and further 
potential for establishing hydrogen-bonded contacts. I am not qualified to 
express an opinion on these findings but can only assume that there is no
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“straightforward” structural relationship between HAl 226 L-^Q change and 
specificity for the a , 2-3 and 0,2-6 linkage.
Various assays for differentiating variant viruses on the basis of their 
receptor binding characteristics involve either chemical or enzymatic 
modification of the receptors on erythrocytes (RBC). Daniels et al, 1987 
performed such haemagglutination tests by adsorbing viruses to derivatised (a 
2,3 or a  2,6) erythrocytes that contained amounts of sialic acid optimal for 
detecting differences in receptor binding properties. X31 was shown to be 
specific for the SA a-2,6 Gal linkage and bound weakly to SA a-2,3- 
derivatised cells even at the highest level of incorporation examined. In 
contrast, X31/HS (226 L->Q) bound to both SA a-2,6 and SA a-2,3 
derivatised erythrocytes (Daniels, et aL, 1987).
In the present investigation, receptor binding specificity was analysed 
by ELISA using either a-2,6 or a-2,3 N-acetyl-lactosaminyl-BSA (SLB) as 
substrates. AU variants exhibited reduced binding for a-2,6 SLB, particularly 
m-7.1 (145, 226), and this was consistent with a critical role for HAl 226 in 
receptor specificity. Interestingly, m-21.2 (135, 225) showed an intermediate 
binding for both a-2,6 and a-2,3 SLB. Another notable finding was that X31- 
HS failed to bind a-2,6 SLB in contrast to X31. This may be because of the 
different assay system used by myself and Daniels et al (RBC agglutination). 
Variant m-1.1 (135, 158) and m -l.lN  (145, 158) also exhibited altered 
receptor binding characteristics. HAl 158 is present on the opposite side of the 
receptor binding pocket and has been implicated in receptor binding specificity.
Thus, Hu transgenic IgM antibodies would appear to preferentiaUy 
select variant viruses with changes in conserved residues of the receptor 
binding pocket. How do I account for such preferential selection?
A likely mechanism may relate to the fact that most IgM antibodies are 
of low affinity, in contrast to neutralising IgG mAbs that have been used to 
characterise HA antigenicaUy. However, to establish that antibody affinity is
152
indeed the determinant for selection of such variants, the next step should be 
measurement of antibody affinity and /or on-rate kinetics. Antibody affinity is 
defined as the strength of interactions between an antigenic determinant and 
the homologous antibody combining site and represents the summation of 
attractive and repulsive forces involved in interaction. Antibody avidity, on the 
other hand, depends in part on affinity but also involves other factors such as 
antibody valency. This means that a higher affinity antibody would bind larger 
amounts of antigen in a shorter period of time (faster on-rates) compared to a 
lower affinity antibody.
Affinity can be measured directly by ELISA, and on-rate kinetics can be 
determined by measuring the velocity of virus neutralisation. A range of 
measured values of affinity constants for the antibody binding site is enormous 
fi*om below 10^  to above 10*^  . The measurement requires
determination of free and antibody-bound antigen at equilibrium. Previously, 
sera containing a heterogeneous population of antibodies of various classes and 
of different affinities, were used and therefore interpretation of results were 
based on an overall affinity estimation which were less accurate. Subsequently 
monoclonal antibodies provided the opportunity to study individual 
homogenous antibodies of known affinity, class and concentration.
Because of the simplicity of the ELISA technique it has been used to 
estimate equilibrium constants directly fi-om solid phase binding of antibody 
(Beatty, et a l, 1987; Li, 1985). These measurements estimate a ‘functional 
affinity’ (Li, 1985)or avidity, the magnitude of which is directly dependent 
upon surface effects. The lack of surface diffusion of antigen and slow 
diffusion rate of ‘bulky antibody molecules’ slows down the association rate of 
antibody and antigen (Beatty, et a l, 1987; Li, 1985). For IgG antibody, 
multivalent binding has been shown to produce a 1000-fold increase in avidity, 
while for IgM the enhancement factor was 10® (Homick and Karush, 1972). 
Thus, if both the reactants, antigen and antibody are multivalent, accuracy will 
not be achieved. This necessitates the preparation of Fab fragments of
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antibody. However, this is where it is problematic to measure “on-rate” 
kinetics for IgM antibodies. IgMs are decavalent and it is difficult to prepare 
Fab fragments of such antibodies. My intention was to compare affinities of 
IgM mAbs that I had generated (and selected double mutants) with IgM mAbs 
from CBA/Ca or BALB/c donors (that had selected X31 variants with single 
changes in known antigenic sites) to see if there was any difference in the “on- 
rate” kinetics. However, very preliminary attempts to employ a plasmon 
resonance technique (BIACOR) have been unsuccessful, due to non-specific 
high backgrounds.
I now wish to consider the findings in the second part of my thesis 
which may be of some relevance to the phenomenon of Original antigenic sin 
- a skewed response during secondary infection such that the antibody 
specificity is directed primarily towards the antigen encountered in the original 
infection (Francis, et al., 1953). Epidemiological studies in humans have shown 
that infection by one subtype confers little or no protective immunity to other 
subtypes, and sera from humans or experimentally infected animals do not 
cross-react with viruses of different subtypes (Knight and Kosel, 1973). After 
infection, individual sera contain antibodies to determinants on the HA of the 
infecting strain that are strain specific as well as cross-reactive antibodies to 
determinants shared by variants of that subtype. In human immune sera that 
have been virus absorbed the proportions of strain-specific and cross-reactive 
antibodies depend on the individual’s previous experience of influenza virus 
infection. In sera from unprimed and naturally infected children, the 
predominant antibodies were strain-specific with only a small amount of cross­
reactive antibody present (Oxford, et a l, 1979a).
In adults who have previously been exposed to an earlier variant, the 
predominant antibodies after infection are cross-reactive but strain-specific 
(Oxford, et a l, 1979b). These studies suggest that antibodies induced by 
recurrent infection with influenza virus were primarily directed toward those 
determinants.
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This brings me to the second part of my thesis where I have tried to 
“mimic” the human situation in mice: individual donors were infected with X31 
and, following hemisplenectomy the recognition specificity for X31 HA was 
examined by the production of mAbs, and the selection and sequencing of their 
corresponding variant viruses. Thereafter mice were re-challenged with an X31 
variant virus (HAl 145 S->I, 158 G->E, del 224-230). My initial aim was to 
see whether the immunodominance observed after initial X31 infection had any 
influence on the repertoire to subsequent challenge with a variant virus.
The potential antibody repertoire of an individual, i.e. the total number 
of possible V-domains that can be generated fi'om the germline is dynamic, and 
of the order of 10^  différent V-domains (Berek, et a l, 1985; Tonegawa, 1983). 
The emergent repertoire produced daily in the bone m a r r o w  is approximately 
3-5x10^ dififerent clones (Opstelten ^and Osmond, 1983). The available 
repertoire, i.e. the number of domains currently expressed, is limited to a 
maximum of 10* specificities, and the actual repertoire which is the V-domains 
used by the effector Ig-secreting cells are about 10® cells (Benner, et a l, 1982). 
However, the normal immune system is dynamic, with high rates of cell 
production and high turnover rates allowing rapid substitution of the major 
part of the immunocompetent cell pool. The size of d if ife re n t antibody 
repertoires, and the dynamic properties of lymphocytes suggest that the 
immune system only uses a minor fi'action of its potential diversity. Repertoires 
can undergo continuous qualitative changes throughout life, and such changes 
can occur at many stages of development. The response to antigenic challenge 
depends on the expressed repertoire, and is therefore of some interest to 
establish whether these are dictated by stochastic events, or germ-line bias, or 
post “antigenic experience”.
Thus, in a sequential infection there might be two possible scenarios: 
(a) either T-memory cells, with a broader specificity than the B-cells, are 
triggered by the cross-reactive antigen and are able to help B-virgin 
lymphocytes to secrete antibodies, or (b) B-memory cells with specificity for
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the first antigen are directly triggered by the cross reactive antigen. In the 
present study, donors were able to generate a neutralising antibody response to 
the variant virus that was also cross-reactive for the wild type virus. In earlier 
studies of original antigenic sin, after a sequential infection with two different 
but antigenically related strains of influenza virus, the antibody stimulated by 
the second infection reacted more strongly with the primary virus than with the 
one actually eliciting the response (Fazekas, and Webster, 1966 a; Fazekas, and 
Webster, 1966 b) - which is what I find!
In the present study, I have examined directly the recognition 
specificity of “recall” mAbs for X31 and its variant virus, by the selection of 
further laboratory variants, X31 variants selected with such antibodies 
(particularly mAb B-3G1), had multiple amino acid substitutions (HAl 193 
S->N, 198 A->E, 226 L->R) or (HAl 198 A->E, 223 V->I). A43 variants 
had a further two substitutions (HAl 145 I—>S, 189 Q—>K), or (145 I->S, 196 
V->A). How can I explain the finding that X31 variants had multiple changes 
both in conserved residues and in antigenic regions? I would speculate again 
that Ab affinity may have played some role in the selection process, as also 
seen in the earlier findings with Hulg mAbs.
The relationships between the amino acid sequences of 
immunoglobulins and the structures of their antigen-binding sites are important 
for understanding the molecular mechanisms for the generation and maturation 
of the immune response. The specificity and affinity of the binding sites are 
governed by the structures of six hypervariable regions (Wu and Kabat, 1970). 
Because hypervariable regions have different sequences in different antibodies, 
each region adopts a different conformation in different antibodies. The 
conformations are determined by the interactions of a few residues at specific 
sites in the hypervariable regions (Chothia, et a l, 1989).
Thus, affinity of an antibody for its antigen influences its biological 
activity. High affinity antibody forms more stable association with antigen than 
lower affinity antibody. Not only do antibodies fi’om different subclasses differ
156
in their affinities, but affinity differences are found within a given subclass 
(Sarvas, et al., 1983). Thus, it is possible that the IgG antibodies generated 
after challenge with the variant virus had lower affinity compared to the ones 
generated earlier. This is speculation on my part and requires further 
investigation and data m e a s u r e m e n t s  of affinity for Fab fragments.
To summarise, I have shown that (probably) low affinity antibodies 
against X31 may preferentially select for substitutions within or proximal to the 
receptor binding pocket. In contrast, moderate to high affinity antibodies for 
the most part select for a single amino acid change within antigenic regions of 
the HA molecule.
Finally, I investigated the recognition specificity of a mAh B 1-9.1 that 
was generated in a BALB/c donor following natural infection. This mAb 
selected a variant with changes at HAl 135 G->V, 226 L—>Q, and fitiled to 
recognise its mutant by ELISA thereby qualifying it as an antigenic variant. In 
previous chapters, I have outlined the importance of residue 226 and how it 
affects receptor binding specificity of the virus. I therefore did further selection 
of X31 variants with mAb Bl-9.1 at different times, and with varying mAb 
concentrations. I found that 6 out of 6 variants had the same amino acid 
changes, HAl 135 G ^R , 158 G->E. Interestingly, the selecting mAb could 
still recognise the laboratory variants HAl 135 G—>R or HAl 158 G—>E in HI 
assays which suggested that the variant had to have both changes in order to 
abrogate recognition by that particular antibody.
I therefore decided to use mAb Bl-9.1 to select a variant of HAl 135 
G->R, and found that the further substitution was indeed HAl 158 G->E. 
However, in addition to HAl 135, 158, the variant also had an amino acid 
substitution at HAl 251. Change at HAl 158 is known to alter receptor 
binding specificity of the virus.
In summary I have found both IgM (from transgenic donors) and IgG 
mAbs (following recurrent infection) preferentially select laboratory variants 
with multiple substitutions in the HAl subunit and altered receptor-binding
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specificity. Affinity measurements of these antibodies might help to establish 
whether low affinity antibodies do indeed select variants with changes in the 
conserved residues that constitute part of the receptor-binding pocket ( fig 5: 
structure of receptor binding pocket).
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APPENDIX I
(Buffers)
Boraie Buffered Saline (BBS), pH 8.6
H 3B O 3
N % B 407
NaCl
Boric add lOQmM
Sodium tetraborate 40mM
Sodium chloride 70mM
Diethartokmune buffer 
(H0CHzCHz.)2NH 
6H2O
NaNa
Diethasolamme 9.7% v/v 
Magnesium chloride
hexalydrate 
Sodium azide
0.49mM 
0.02% w/v
Phosphate buffered saline (PBS)
NazHPOi Di-sodium hydrogen pho^hate lOOmM
K H 2P O 4  Potassium di-hydrpgen phoq)hate 1.8mM
NaCl Sodium chloride 171mM
Kd Potassium chloride 3.4mM
Tris/Borate buffer (TBE)
Tris-base 89mM
Boric add 89mM
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EDTA 2mM
Tris/Gfycine buffer 8.3)
Tris-HQ 25mM
Glycine 3S4mM
SDS 0.1%
Tris/saline buffer
Tris-HCl
EDTA
SDS
lOmM
ImM
l%w/v
LoatUrg buffer (TKjn-re(kumtg)
Urea 8.3M
SDS 0.6% w/v
Cootnasse bhie 0.01% w/v
Loadmg buffer (reducing)
Urea 8.3 M
SDS 0.6% w/v
Coomassie bhie 0.01% w/v
2-Me 0.46M
(An chemicals fiom BDH laboratory supplies)
